Polymerase enzymes, compositions and methods of use
By introducing specific amino acid substitution mutations into archaea B family DNA polymerases, the problems of high error rate and fast phase fixation rate of DNA polymerases under rapid cycling times have been solved, improving the accuracy and efficiency of nucleotide incorporation and making it suitable for nucleotide incorporation reactions in nucleic acid synthesis sequencing.
Patent Information
- Application Number
- CN202380031832.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-20
- Filing Date
- 2023-09-29
- Publication Date
- 2024-11-26
AI Technical Summary
Existing DNA polymerases suffer from high error rates and fast phase fixation rates during rapid-cycle nucleic acid synthesis and sequencing, making it difficult to effectively incorporate modified nucleotides containing 3'-OH acetal or 3'-OH thiocarbamate end groups.
By introducing specific amino acid substitution mutations into archaea B family DNA polymerases, their nucleotide incorporation performance under rapid cycling times was improved, resulting in reduced error rate and phase fixation rate, and increased incorporation rate.
This approach improves the accuracy of DNA polymerase under rapid cycle time conditions, reduces error rate and phase fixation rate, and enhances the quality and efficiency of nucleic acid sequencing.
Smart Images

Figure CN119032165A_ABST
Abstract
Description
[0001] Continuing application data
[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 412,241, filed on September 30, 2022, and U.S. Provisional Application Serial No. 63 / 433,971, filed on December 20, 2022, each of which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted electronically to the United States Patent and Trademark Office via EFS-Web as an XML file named "0531.00238US01.xml", 53,163 bytes in size and created on September 5, 2023. The information contained in the sequence listing is incorporated herein by reference. Technical Field
[0005] The present disclosure relates particularly to altered polymerases for performing nucleotide incorporation reactions, particularly in the context of nucleic acid sequencing by synthesis. Background Art
[0006] Synthesis sequencing (SBS) technology relies on DNA polymerase and modified nucleotides as components of the sequencing process. Modified nucleotides generally include 3'-hydroxyl protecting groups (also referred to as blocking groups) to prevent the bases on the nucleotides from being added by DNA polymerase after the polymerase incorporates additional nucleotides into the polynucleotide chain. After determining the identity of the added bases, the 3'-hydroxyl protecting group is removed, and the next modified nucleotide is added by the polymerase. Available protecting groups prevent additional nucleotides from being added to the polynucleotide chain and are reversible, for example, can be easily removed from the sugar portion of the nucleotide without causing damage to the polynucleotide chain. In addition, modified nucleotides need to be compatible with the polymerase used to incorporate them into the polynucleotide chain. Summary of the invention
[0007] The present disclosure provides polymerases with improved rates of incorporation of modified nucleotides, such as described in US Pat. No. 11,293,061. When tested under rapid cycle time SBS conditions with the second generation fully functional nucleotides described herein, these polymerases exhibited sequencing performance superior to enzymes currently employed in SBS.
[0008] Provided herein are altered archaeal B-family DNA polymerases. In one embodiment, the altered archaeal B-family DNA polymerase comprises an amino acid substitution mutation at a position that is functionally equivalent to an amino acid in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1; and an amino acid substitution mutation at each of the following positions: an amino acid substitution mutation to Leu at position Arg58; an amino acid substitution mutation to Gly at position Tyr261; an amino acid substitution mutation to Gly or Val at position Asn269; an amino acid substitution mutation to Ile or Lys at position Phe283; an amino acid substitution mutation to Lys at position Phe284; an amino acid substitution mutation to Lys at position Phe285; an amino acid substitution mutation to Lys at position Phe287; an amino acid substitution mutation to Lys at position Phe288; an amino acid substitution mutation to Lys at position Phe289; an amino acid substitution mutation to Lys at position Phe290; an amino acid substitution mutation to Lys at position Phe291; an amino acid substitution mutation to Lys at position Phe293; an amino acid substitution mutation to Lys at position Phe294; an amino acid substitution mutation to Lys at position Phe295; an amino acid substitution mutation to Lys at position Phe296; an amino acid substitution mutation to Lys at position Phe297; an amino acid substitution mutation to Lys at position Phe298; an amino acid substitution mutation to Lys at position Phe299; an amino acid substitution mutation to Lys at position Phe299; an amino acid substitution mutation to Lys at position Phe298; an amino acid substitution mutation to Lys at position Phe amino acid substitution mutation to Asp at position Met328; amino acid substitution mutation to Thr at position Met329; amino acid substitution mutation to Ser at position Gln332; amino acid substitution mutation to His or Ile at position Leu333; amino acid substitution mutation to Asp or Arg or Glu or Val or Thr at position Ser347; amino acid substitution mutation to Met or Ala at position Asn399; amino acid substitution mutation to Met or Lys or Gln at position Phe405; amino acid substitution mutation to Met at position Arg406; amino acid substitution mutation to Ile41 amino acid substitution mutation to Val at position 0; amino acid substitution mutation to Val at position Ile412; amino acid substitution mutation to Gly at position Glu458; amino acid substitution mutation to Thr or Asp at position Glu459; amino acid substitution mutation to Trp at position Gln461; amino acid substitution mutation to Glu at position Ala469; amino acid substitution mutation to Ile at position Tyr481; amino acid substitution mutation to Asn or Gly or Met or Gln or Ser or Thr at position Val485; amino acid substitution mutation to Leu at position Ile486 amino acid substitution mutation to Asn at position Trp504; amino acid substitution mutation to His or Pro at position Lys507; amino acid substitution mutation to Lys or Met or Arg at position Glu511; amino acid substitution mutation to Ile or Lys or Met or Gln or Leu at position Trp516; amino acid substitution mutation to Ala at position Tyr520; amino acid substitution mutation to Thr at position Ile521; amino acid substitution mutation to Ile or Thr at position Met523; amino acid substitution mutation to Asn at position Arg526;An amino acid substitution mutation to Ile at position Glu527; an amino acid substitution mutation to Thr at position Leu528; an amino acid substitution mutation to Leu at position Ile567; an amino acid substitution mutation to Gln at position Asn568; an amino acid substitution mutation to Phe or Ile or Met or Trp at position Leu571; an amino acid substitution mutation to Leu at position Glu576; an amino acid substitution mutation to Ile or Lys or Gln or Arg or Val or Met at position Glu580; an amino acid substitution mutation to Lys at position Thr590; an amino acid substitution mutation to Met at position Ala595; or an amino acid substitution mutation to Asp at position Ile603. The present disclosure also provides an altered archaeal B family DNA polymerase, the altered archaeal B family DNA polymerase comprising at least two amino acid substitution mutations, at least three amino acid substitution mutations, at least four amino acid substitution mutations, or at least five amino acid substitution mutations. ;
[0009] Also provided herein are altered B-family DNA polymerases. In one embodiment, the altered B-family DNA polymerase comprises an amino acid sequence at least 80% identical to the amino acid sequence SEQ ID NO: 1 and one or more substitution mutations as described herein. In another embodiment, the altered B-family DNA polymerase is an altered archaeal B-family DNA polymerase comprising one or more substitution mutations as described herein. The one or more substitution mutations include, but are not limited to, an amino acid substitution mutation at a position functionally equivalent to Glu580 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, an amino acid substitution mutation at a position functionally equivalent to Phe405 and Val485 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, an amino acid substitution mutation at a position functionally equivalent to Phe405 and Ile410 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, an amino acid substitution mutation at a position functionally equivalent to Phe140 and Ser407 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, an amino acid substitution mutation at a position functionally equivalent to Leu403, Ala408, Ile410 and Gly497 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, an amino acid substitution mutation at a position functionally equivalent to Phe405 and Ile410 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1 The invention relates to an amino acid substitution mutation at positions Phe405, Ile410, Ile412, Thr514 and Ile521 in a reference archaeal B family DNA polymerase of SEQ ID NO:1, or an amino acid substitution mutation at positions Phe405, Ala408, Ile410, Ile412, Thr514, Ile521 in a reference archaeal B family DNA polymerase of SEQ ID NO:1 that is functionally equivalent to Phe405, Ala408, Ile410, Ile412, Thr514, Ile521 in a reference archaeal B family DNA polymerase of SEQ ID NO:1, wherein the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:1. In one embodiment,
[0010] Unless otherwise indicated, the terms used herein should be understood to have their ordinary meanings in the relevant art. Several terms used herein and their meanings are listed below.
[0011] The term "and / or" means one or all of the listed elements, or a combination of any two or more of the listed elements.
[0012] The words "preferred" and "preferably" refer to embodiments of the present invention that may provide certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present invention.
[0013] The terms "include" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.
[0014] It should be understood that anywhere an embodiment is described herein with the language "comprising," "including," or "containing," etc., other similar embodiments described with "consisting of" and / or "consisting essentially of" are also provided.
[0015] Unless otherwise specified, "a," "an," "the," and "at least one" are used interchangeably to mean one or more than one.
[0016] "Suitable" conditions or "appropriate" conditions for an event to occur are conditions that do not prevent such an event from occurring. Thus, these conditions allow, enhance, promote and / or facilitate the event.
[0017] As used herein, "providing" in the context of a polymerase or composition means preparing the polymerase or composition, purchasing the polymerase or composition, or otherwise obtaining the polymerase or composition.
[0018] Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
[0019] References throughout this specification to "one embodiment," "embodiment," "certain embodiments," or "some embodiments" and the like mean that a particular feature, configuration, composition, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present disclosure. Therefore, multiple appearances of such phrases throughout this specification do not necessarily refer to the same embodiment of the present disclosure. Furthermore, in one or more embodiments, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner.
[0020] The above summary of the invention of the present disclosure is not intended to describe each disclosed embodiment or each specific implementation of the present disclosure. The following description more specifically illustrates exemplary embodiments. In several places throughout the application, guidance is provided by lists of examples, which can be used in various combinations. In each case, the cited lists are used only as representative groups and should not be interpreted as exclusive lists. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The following detailed description of illustrative embodiments of the present disclosure is best understood when read in conjunction with the following drawing figures.
[0022] Fig. 1 is a schematic diagram showing the alignment of polymerase amino acid sequences from Thermococcus sp. 9°N-7 (9°N, SEQ ID NO: 9), Thermococcus litoralis (Vent, SEQ ID NO: 10 and Deep Vent, SEQ ID NO: 11), Thermococcus waiotapuensis (Twa, SEQ ID NO: 12), Thermococcus kodakarensis (KOD, SEQ ID NO: 13), Pyrococcus furiosus (Pfu, SEQ ID NO: 14), Pyrococcus abyssi (Pab, SEQ ID NO: 15). "*" (asterisk) indicates a position with a single completely conserved residue between all polymerases. ":" (colon) indicates conservation between groups with strong similar properties - roughly equivalent to a score > 0.5 in the Gonnet PAM 250 matrix. "." (period) indicates conservation between groups with weak similar properties - roughly equivalent to a score = < 0.5 and > 0 in the Gonnet PAM 250 matrix.
[0023] FIG. 2A to FIG. 2B Some exemplary mutations considered for secondary screening are shown.
[0024] Figure 3 The performance of rank 1 mutants generated by the secondary screen is shown.
[0025] FIG. 4A to FIG. 4B The performance of rank 2 mutants generated by the secondary screen is shown.
[0026] Figure 5 An example of the performance of double mutants during the secondary screen is shown.
[0027] Figure 6 Examples are shown for polymerases tested with short incubation times (20 s) in a 150 cycle run (Polymerases A, B, E, F, H, I, J, L, N, and O).
[0028] Figure 7 Shown is a comparison of polymerase performance over a 150 cycle run at short incorporation times.
[0029] FIG. 8 shows the amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 32.
[0030] The schematic diagrams are not necessarily drawn to scale. Like reference numbers used in the drawings refer to similar components, steps, etc. However, it should be understood that the use of numbers to refer to components in a given figure is not intended to limit the components labeled with the same number in another figure. In addition, the use of different numbers to refer to components is not intended to indicate that the differently numbered components cannot be the same or similar to the other numbered components. DETAILED DESCRIPTION
[0031] Polymerase
[0032] Provided herein are polymerases, compositions and kits comprising polymerases, and methods of using polymerases. Polymerases described herein are DNA polymerases. In one embodiment, polymerases disclosed herein (also referred to herein as "modified polymerases") are based on the amino acid sequence of a reference polymerase. When compared to a reference polymerase, the modified polymerase includes substitution mutations at one or more residues. Compared to a reference polymerase, the substitution mutations may be located at the same position or at a functionally equivalent position. Reference polymerases and functionally equivalent positions are described herein. Those skilled in the art will readily appreciate that modified polymerases disclosed herein are not naturally occurring.
[0033] Compared with reference polymerase, the changed polymerase described herein has useful activity. Reference polymerase described herein can be used in the SBS reaction of the modified nucleotide with 3'-OH acetal blocking group or 3'-OH thiocarbamate blocking group. The modified nucleotide with 3'-OH acetal blocking group or 3'-OH thiocarbamate blocking group is referred to as " second generation fully functional nucleotide " or " second generation FFN" in this article. In one or more embodiments, second generation FFN can also include cleavable joint. Second generation FFN is described herein. Unless otherwise specified, the description of incorporating nucleotide by polymerase herein is to incorporate second generation FFN.
[0034] Reference polymerases described herein have useful error rates in SBS reactions when using second-generation ffNs and standard incorporation rates; however, using reference polymerases in SBS reactions with rapid incorporation times increases error rates. Performance that maintains or exceeds current levels at faster incorporation times can be assisted by a new generation of polymerases. DNA polymerases with significantly improved performance under conditions of SBS rapid cycle times with second-generation ffNs are provided herein. The inventors have surprisingly identified certain altered polymerases that exhibit improved characteristics, including improved accuracy during the rapid incorporation time of second-generation ffNs. Improved accuracy includes reduced error rates and reduced phasing, and results in improved quality metrics in SBS reactions. Therefore, compared to a reference sequence (such as a reference sequence SEQ ID NO: 1), the altered polymerases disclosed herein have one or more activities selected from the incorporation rate of a lower error rate, a lower phasing rate and / or an increased second-generation ffN.
[0035] "Error rate" refers to a measure of the frequency of errors in identifying the correct base (i.e., the complementary sequence of the template sequence at a specific position) when a cluster is read during a sequencing reaction. The fidelity of the match between the sequencing library and the original genomic sequence can vary depending on the frequency of base mutations that occur at any stage from nucleic acid extraction to its sequencing on the sequencing platform. This frequency sets an upper limit on the probability that the sequenced base is correct. In some embodiments, the quality score is presented as a numerical value. For example, the quality score can be cited as QXX, where XX is a fraction and means that the error probability of this particular read is 10 -XX / 10 Thus, as an example, Q30 equals 1 / 1000 or 0.1% error rate, and Q40 equals 1 / 10,000 or 0.01% error rate.
[0036] Phasing is a term known to those skilled in the art, and is used to describe the loss of synchronization in the readout of the sequence copies of the cluster. Phasing causes the extracted intensity of a particular cycle to include the signal of the current cycle and the noise from the current cycle. Therefore, as used herein, the term "phasing" refers to a phenomenon in SBS, which is caused by the incomplete incorporation of nucleotides in some parts of the DNA chain within the cluster by the polymerase in a given sequencing cycle, and is therefore a measure of the rate at which the single molecules within the cluster lose synchronization with each other. Phasing can be measured during the detection of the cluster signal of each cycle, and can be reported as the percentage of detectable signals from the cluster that are not synchronized with the signal in the cluster. As an example, the cluster is detected by the "green" fluorescent group signal during cycle N. In the subsequent cycle (cycle N+1), 99.9% of the cluster signal is detected in the "red" channel, and 0.1% of the signal is still from the previous cycle and is detected in the "green" channel. The result will show that phasing is occurring and can be reported as a numerical value, such as a phasing value of 0.1, indicating that 0.1% of the molecules in the cluster lag behind in each cycle.
[0037] Detection of phasing can be performed and reported according to any suitable method known in the art, for example, as described in U.S. Pat. No. 8,965,076 and U.S. Provisional Patent No. 62 / 535,558. For example, as described in the Examples below, phasing is routinely detected and reported during an SBS sequencing run on a sequencing instrument, such as a HiSeq from Illumina, Inc. (San Diego, CA). TM 、Genome Analyzer TM 、NextSeq TM 、NextSeq 1000 TM 、NextSeq2000 TM 、NovaSeq TM 、iSeq TM 、MiniSeq TM or MiSeq TM sequencing platform or any other suitable instrument known in the art.
[0038] In some embodiments, the polysaccharide of this invention can be used for the preparation of the polysaccharide of the present invention.The shortening of cycle time can increase the generation of phasing, thereby causes error rate.The discovery of the sudden change of the polysaccharide of changed as herein described is unexpected, and provides very big advantage in SBS application, and the sudden change of this polysaccharide of changed reduces the incidence rate of phasing when using under the fast cycle time condition of second generation FFN.For example, when using second generation FFN, the polysaccharide of changed can provide faster SBS cycle time and lower phasing, and optionally provides longer sequencing read length.The error rate of the polysaccharide of changed as provided herein and the characterization of phasing are set forth in the following examples part.
[0039] In one embodiment, when the altered polymerase is tested using a fast incorporation time, the error rate is reduced compared to the enzyme currently employed in SBS (such as SEQ ID NO: 1). Incorporation refers to the amount of time that the DNA polymerase is in contact with the template. As used herein, a slow incorporation time is a time when using MiniSeq TM Incorporation time used under the standard cycle of a desktop sequencing system. Slow incorporation time includes 40 seconds to 50 seconds. As used herein, rapid cycle time refers to an incorporation step of 10 seconds to 40 seconds. In one embodiment, the SBS rapid cycle time condition is that the incorporation time is not more than 40 seconds, not more than 30 seconds, not more than 20 seconds, not more than 18 seconds, not more than 16 seconds, not more than 14 seconds, not more than 12 seconds or not more than 10 seconds. In one embodiment, the SBS rapid cycle time condition is that the incorporation time is at least 10 seconds, at least 12 seconds, at least 14 seconds, at least 16 seconds, at least 18 seconds, at least 20 seconds or at least 30 seconds.
[0040] The modified polymerase described herein can be used for the SBS reaction of different lengths. "Running" refers to the number of nucleotides identified on the template. The operation generally includes the operation of the first primer (e.g., read1 primer) based on a chain of the template and the operation of the second primer (e.g., read2 primer) based on the complementary chain of the template. In one embodiment, the number of nucleotides identified using the first primer or the second primer can be 10 to 300 nucleotides. In one embodiment, the number of nucleotides identified using the first primer or the second primer can be no more than 300 nucleotides, no more than 250 nucleotides, no more than 200 nucleotides, no more than 150 nucleotides, no more than 150 nucleotides, no more than 130 nucleotides, no more than 110 nucleotides, no more than 90 nucleotides, no more than 70 nucleotides, no more than 50 nucleotides, no more than 30 nucleotides or no more than 20 nucleotides. In one embodiment, the number of nucleotides identified using the first primer or the second primer can be at least 10, at least 20, at least 30, at least 50, at least 70, at least 90, at least 110, or at least 130 nucleotides.
[0041] In certain embodiments, the altered polymerase is based on a B-family DNA polymerase. The altered polymerase can be based on, for example, a B-family archaeal DNA polymerase, human DNA polymerase-α, or a bacteriophage polymerase. An altered polymerase of the present disclosure "based on" a B-family DNA polymerase means that the altered polymerase is a B-family DNA polymerase comprising one or more of the substitution mutations described herein. An altered polymerase of the present disclosure "based on" a B-family DNA polymerase may also include one or more conservative mutations and / or one or more non-conservative mutations as described herein.
[0042] Family B archaeal DNA polymerases are well known in the art, as exemplified by the disclosure of US Patent No. 8,460,910. In certain embodiments, the altered polymerases of the present disclosure are based on a Family B archaeal DNA polymerase from a hyperthermophilic archaeon and are thermostable.
[0043] In certain embodiments, the Family B archaeal DNA polymerase is from a genus such as, for example, Thermococcus, Pyrococcus, Methanococcusm, Pyrobaculum, Pyrodictium, and Aeropyrum. Members of the genus Thermococcus are well known in the art and include, but are not limited to, T.4557, T.barophilus, T.gammatolerans, T.onnurineus, T.sibiricus, T.sibiricus, T.gorgonarius, T.gorgonarius (TGO), and T.waotapense. Members of the genus Pyrococcus are well known in the art, and include but are not limited to P.NA2, Pyrococcus abyssinus, Pyrococcus abyssinus, Pyrococcus horikoshii, Pyrococcus yayanosii, Pyrococcus endeavori, Pyrococcus glycovorans, and Pyrococcus woesei. Members of the genus Methanococcus are well known in the art, and include but are not limited to M.aeolicus, M.maripaludis, M.vannielii, M.voltae, M.thermolithotrophicus, and M.jannaschii. Members of the genus Pyrococcus are well known in the art, and include but are not limited to P.calidifontis, Pc. Members of the genus Pyrococcus are well known in the art, and include but are not limited to Pyrococcus occultus. Members of the genus A. pernix are well known in the art and include, but are not limited to, A. pernix.
[0044] In one embodiment, the altered B family DNA polymerase is based on Deep 9°N, Pfu, KOD, or Pab polymerase. and Deep is a commercial name for a B-family DNA polymerase isolated from the hyperthermophilic archaeon Thermococcus littoralis. 9°N polymerase is a B-family polymerase isolated from Thermococcus 9°N-7. Pfu polymerase is a B-family polymerase isolated from Pyrococcus furiosus. KOD polymerase is a B-family polymerase isolated from Thermococcus xiaobaodao. Pab polymerase is a B-family polymerase isolated from Pyrococcus fusilis. Twa is a B-family polymerase isolated from Thermococcus waotapense. The following is disclosed in FIG. Deep Examples of 9°N, Pfu, KOD, Pab, and Twa polymerases.
[0045] In certain embodiments, the altered polymerase is based on a B-family DNA polymerase from a bacteriophage, such as, for example, T4, RB69, or phi29 phage.
[0046] Fig. 1 shows the sequence alignment of the protein with the amino acid sequence shown in SEQ ID NO:9 to SEQ ID NO:15.This alignment shows the amino acid that is conserved in different B family polymerases.It will be appreciated by those skilled in the art that the conservative amino acids and conservative regions are conservative, probably because they are important to the function of the polymerase, and therefore show the correlation between the structure and function of the polymerase.This alignment also shows the variable regions across different B family polymerases.One of ordinary skill in the art can infer from these data that substitutions, particularly conservative substitutions, can be allowed without excessively affecting the polymerase region of the biological activity of the altered polymerase.
[0047] The altered polymerase described herein can be based on the amino acid sequence of a known polymerase (also referred to herein as a reference polymerase), and also includes substitution mutations at one or more residues. In one embodiment, the substitution mutation is located at a position that is functionally equivalent to the amino acid of the reference polymerase. "Functionally equivalent" means that the altered polymerase has an amino acid substitution at an amino acid position in the reference polymerase that has the same functional role in the reference polymerase and the altered polymerase.
[0048] Typically, functionally equivalent substitution mutations in two or more different polymerases occur at homologous amino acid positions in the amino acid sequences of these polymerases. Therefore, the term "functionally equivalent" as used herein also encompasses mutations "positionally equivalent" or "homologous" to a given mutation, regardless of whether the specific function of the amino acid of the mutation is known. The positions of amino acid residues that are functionally equivalent and positionally equivalent in the amino acid sequences of two or more different polymerases can be identified based on sequence alignment and / or molecular modeling. An example of sequence alignments identifying positionally equivalent and / or functionally equivalent residues is shown in Figure 1. For example, the residues arranged vertically in the Twa, KOD, Pab, Pfu, Deep Vent and Vent polymerases of Figure 1 are considered to be positionally equivalent and functionally equivalent to the corresponding residues in the 9 ° N polymerase amino acid sequence. Therefore, for example, the residue 358 of 9 ° N, Twa, KOD, Pfu, Deep Vent and Pab polymerases is functionally equivalent and positionally equivalent to the residue 360 of Vent polymerase. Likewise, for example, residue 633 of 9°N, Twa, KOD, and Pab polymerases, residue 634 of Pfu and Deep Vent polymerases, and residue 636 of Vent polymerase are functionally equivalent and positionally equivalent. Functionally equivalent residues in DNA polymerases can be readily identified by one skilled in the art.
[0049] In certain embodiments, the substitution mutation comprises a mutation to a residue with a non-polar side chain. Amino acids with non-polar side chains are well known in the art and include, for example, alanine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine.
[0050] In certain embodiments, the substitution mutation includes a mutation to a residue with a polar side chain. Amino acids with polar side chains are well known in the art and include, for example, arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, cysteine, tyrosine and threonine.
[0051] In certain embodiments, the substitution mutation comprises a mutation to a residue with a hydrophobic side chain. Amino acids with hydrophobic side chains are well known in the art and include, for example, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan.
[0052] In certain embodiments, the substitution mutation comprises a mutation to a residue with an uncharged side chain. Amino acids with uncharged side chains are well known in the art and include, for example, glycine, serine, cysteine, asparagine, glutamine, tyrosine and threonine.
[0053] In one or more embodiments, the altered polymerase has an amino acid sequence that is structurally similar to a reference polymerase disclosed herein. In one embodiment, the reference polymerase is a polymerase comprising the amino acid sequence of Archaebacterial Family B DNA polymerase 1901, also referred to herein as Pol 1901 (SEQ ID NO: 1). Other reference sequences include SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, wherein the substitution mutations are functionally equivalent to the following substitution mutations in SEQ ID NO: 1: Met129Ala, Aspl41Ala, Glu143Ala, Cys223Ser, Arg247Tyr, Thr349Lys, Leu408Ala, Tyr409Ala, Pro410Ile, Ala485Val, Tyr497Gly, Glu599Asp, and His633Gly.
[0054] As used herein, an altered polymerase may be "structurally similar" to a reference polymerase if the amino acid sequence of the altered polymerase has a specified amount of sequence similarity and / or sequence identity compared to the reference polymerase.
[0055] The structural similarity of two amino acid sequences can be determined by aligning the residues of the two sequences (e.g., a candidate polymerase and a reference polymerase as described herein) to optimize the number of identical amino acids along the length of their sequences; in order to optimize the number of identical amino acids, gaps in either or both sequences are allowed when aligning, although the amino acids in each sequence must remain in their correct order. A candidate polymerase is a polymerase to which a reference polymerase is compared. A candidate polymerase that has structural similarity and polymerase activity with a reference polymerase is an altered polymerase.
[0056] Pairwise comparison analysis of amino acid sequences or nucleotide sequences can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981); the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970); by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988); by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.); or by visual inspection (see generally, Current Protocols in Molecular Biology, Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., supplemented to 2004).
[0057] Unless otherwise specified herein, the algorithm used to determine structural similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215: 403-410 (1990). Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm includes first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which, when aligned with words of the same length in the database sequence, match or satisfy a positive threshold score T. T is referred to as the neighborhood word score threshold (Altschul et al., J. Mol. Biol. 215: 403-410 (1990)). These initial adjacent word hits serve as seeds for initiating searches to find longer HSPs containing these word hits. Then, these word hits are extended in both directions along each sequence until the cumulative alignment score can be increased. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatched residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction is stopped when the following occurs: the cumulative alignment score drops by an amount X from its maximum achieved value; the cumulative score drops to zero or lower due to the accumulation of one or more negative scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both chains as defaults. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).
[0058] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One similarity measure provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
[0059] In the comparison of two amino acid sequences, structural similarity can be expressed by "identity" percentage or can be expressed by "similarity" percentage. "Identity" refers to the presence of identical amino acids. "Similarity" refers to not only the presence of identical amino acids, but also the presence of conservative substitutions. Conservative substitutions of amino acids in proteins can be selected from other members of the class to which the amino acid belongs. For example, it is well known in the field of protein biochemistry that amino acids belonging to an amino acid group with a specific size or characteristic (such as charge, hydrophobicity or hydrophilicity) can be replaced by another amino acid without changing the activity of the protein, particularly in protein regions that are not directly related to biological activity. For example, non-polar amino acids include alanine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine. Hydrophobic amino acids include glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan. Polar amino acids include arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, cysteine, tyrosine and threonine. Uncharged amino acids include glycine, serine, cysteine, asparagine, glutamine, tyrosine, and threonine.
[0060] Thus, as used herein, reference to a polymerase as described herein, such as reference to the amino acid sequence of one or more SEQ ID NOs described herein can include proteins having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% amino acid sequence similarity to the reference polymerase.
[0061] Alternatively, as used herein, reference to a polymerase as described herein, such as reference to the amino acid sequence of one or more SEQ ID NOs described herein can include proteins having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% amino acid sequence identity with the reference polymerase.
[0062] The present disclosure describes mutations that cause a polymerase to have one or more of the polymerase activities described herein. Compared to a reference polymerase (such as SEQ ID NO: 1), the polymerase described herein can include any number of mutations, e.g., at least 1, at least 2, at least 3, at least 4, or at least 5 mutations. Likewise, the polymerase described herein can include any combination of mutations.
[0063] In one or more embodiments, the altered B family polymerase described herein includes a substitution mutation at a position functionally equivalent to R58, Y261, N269, F283, P328, M329, Q332, L333, S347, N399, F405, R406, 1410, 1412, E458, E459, Q461, A469, Y481, V485, 1486, W504, K507, E511, W516, Y520, 1521, M523, R526, E527, 1567, N568, L571, E576, E580, T590, A595, or 1603 in Pol 1901 (SEQ ID NO: 1).
[0064] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Arg58 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Arg58 is a mutation to a non-polar or hydrophobic amino acid (e.g., Leu).
[0065] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Tyr261 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Tyr261 is a mutation to a non-polar, hydrophobic or uncharged amino acid (e.g., Gly).
[0066] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Asn269 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Asn269 is a mutation to a non-polar amino acid (e.g., Gly or Val). In one embodiment, the substitution mutation at a position functionally equivalent to Asn269 is a mutation to a hydrophobic amino acid (e.g., Gly or Val). In one embodiment, the substitution mutation at a position functionally equivalent to Asn269 is a mutation to an uncharged amino acid (e.g., Gly).
[0067] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Phe283 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Phe283 is a mutation to a non-polar, hydrophobic or uncharged amino acid (e.g., Ile). In one embodiment, the substitution mutation at a position functionally equivalent to Phe283 is a mutation of polarity (e.g., Lys).
[0068] In one embodiment, the altered B family polymerase comprises a substitution mutation at a position functionally equivalent to Pro328 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Pro328 is a mutation to a polar or uncharged amino acid (e.g., Asp).
[0069] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Met329 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Met329 is a mutation to a polar or uncharged amino acid (e.g., Thr).
[0070] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Gln332 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Gln332 is a mutation to a polar or uncharged amino acid (e.g., Ser).
[0071] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Leu333 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Leu333 is a mutation to a polar amino acid (e.g., His). In one embodiment, the substitution mutation at a position functionally equivalent to Leu333 is a mutation to a non-polar amino acid (e.g., Ile). In one embodiment, the substitution mutation at a position functionally equivalent to Leu333 is a mutation to a hydrophobic amino acid (e.g., Ile).
[0072] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to S347 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to S347 is a mutation to a polar amino acid (e.g., Asp, Arg, or Glu). In one embodiment, the substitution mutation at a position functionally equivalent to S347 is a mutation to a non-polar amino acid (e.g., Val). In one embodiment, the substitution mutation at a position functionally equivalent to S347 is a mutation to a hydrophobic amino acid (e.g., Val). In one embodiment, the substitution mutation at a position functionally equivalent to S347 is a mutation to a polar or uncharged amino acid (e.g., Thr).
[0073] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Asn399 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Asn399 is a mutation to a non-polar amino acid (e.g., Ala or Met). In one embodiment, the substitution mutation at a position functionally equivalent to Asn399 is a mutation to a hydrophobic amino acid (e.g., Ala or Met).
[0074] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Phe405 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to a non-polar amino acid or a hydrophobic amino acid (e.g., Met). In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to a polar amino acid (e.g., Lys and Gln). In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to an uncharged amino acid (e.g., Gln). In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to Met. In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to Lys.
[0075] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Arg406 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Arg406 is a mutation to a non-polar or hydrophobic amino acid (e.g., Met).
[0076] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile410 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile410 is a mutation to a polar or uncharged amino acid (e.g., Ser).
[0077] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile412 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile412 is a mutation to a non-polar amino acid (e.g., Val). In one embodiment, the substitution mutation at a position functionally equivalent to Ile412 is a mutation to a hydrophobic amino acid (e.g., Val).
[0078] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu458 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu458 is a mutation to a non-polar, hydrophobic or uncharged amino acid (e.g., Gly).
[0079] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu459 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu459 is a mutation to a polar or uncharged amino acid (e.g., Thr). In one embodiment, the substitution mutation at a position functionally equivalent to Glu459 is a mutation to a polar or uncharged amino acid (e.g., Asp).
[0080] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Gln461 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Gln461 is a mutation to a polar amino acid (e.g., Tyr). In one embodiment, the substitution mutation at a position functionally equivalent to Gln461 is a mutation to an uncharged amino acid (e.g., Tyr).
[0081] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ala469 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ala469 is a mutation to a polar amino acid (eg, Glu).
[0082] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Tyr481 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Tyr481 is a mutation to a non-polar amino acid (e.g., Ile).
[0083] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Val485 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Val485 is a mutation to a non-polar or hydrophobic amino acid (e.g., Met or Gly, preferably Gly). In one embodiment, the substitution mutation at a position functionally equivalent to Val485 is a mutation to a polar amino acid (e.g., Lys, Asn, Gln, Ser or Thr, preferably Asn or Lys). In one embodiment, the substitution mutation at a position functionally equivalent to Val485 is a mutation to a hydrophobic amino acid (e.g., Gly). In one embodiment, the substitution mutation at a position functionally equivalent to Val485 is a mutation to an uncharged amino acid (e.g., Asn, Gly, Gln, Ser or Thr).
[0084] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile486 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile486 is a mutation to a non-polar amino acid (e.g., Leu). In one embodiment, the substitution mutation at a position functionally equivalent to Ile486 is a mutation to a hydrophobic amino acid (e.g., Leu).
[0085] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Trp504 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Trp504 is a mutation to a polar amino acid (e.g., Asn). In one embodiment, the substitution mutation at a position functionally equivalent to Trp504 is a mutation to an uncharged amino acid (e.g., Asn).
[0086] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Lys507 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Lys507 is a mutation to a polar amino acid (e.g., His). In one embodiment, the substitution mutation at a position functionally equivalent to Lys507 is a mutation to a non-polar or hydrophobic amino acid (e.g., Pro).
[0087] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu511 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu511 is a mutation to a polar amino acid (e.g., Arg or Lys). In one embodiment, the substitution mutation at a position functionally equivalent to Glu511 is a mutation to a non-polar amino acid (e.g., Met). In one embodiment, the substitution mutation at a position functionally equivalent to Glu511 is a mutation to a hydrophobic amino acid (e.g., Met).
[0088] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Trp516 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Trp516 is a mutation to a polar amino acid (e.g., Gln or Lys). In one embodiment, the substitution mutation at a position functionally equivalent to Trp516 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ile or Met). In one embodiment, the substitution mutation at a position functionally equivalent to Trp516 is a mutation to a hydrophobic amino acid (e.g., Ile). In one embodiment, the substitution mutation at a position functionally equivalent to Trp516 is a mutation to an uncharged amino acid (e.g., Gln). In one embodiment, the substitution mutation at a position functionally equivalent to Trp516 is a mutation to an uncharged amino acid (e.g., Leu).
[0089] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Tyr520 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Tyr520 is a mutation to a non-polar amino acid (e.g., Ala). In one embodiment, the substitution mutation at a position functionally equivalent to Tyr520 is a mutation to a hydrophobic amino acid (e.g., Ala).
[0090] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile521 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile521 is a mutation to a polar or uncharged amino acid (e.g., Thr).
[0091] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Met523 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Met523 is a mutation to a polar or uncharged amino acid (e.g., Thr). In one embodiment, the substitution mutation at a position functionally equivalent to Met523 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ile).
[0092] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Arg526 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Arg526 is a mutation to a polar or uncharged amino acid (e.g., Asn).
[0093] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu527 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu527 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ile).
[0094] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Leu528 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Leu528 is a mutation to a polar or uncharged amino acid (e.g., Thr).
[0095] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile567 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile567 is a mutation to a non-polar amino acid (e.g., Leu). In one embodiment, the substitution mutation at a position functionally equivalent to Ile567 is a mutation to a hydrophobic amino acid (e.g., Leu).
[0096] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Asn568 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Asn568 is a mutation to a polar amino acid (e.g., Gln). In one embodiment, the substitution mutation at a position functionally equivalent to Asn568 is a mutation to an uncharged amino acid (e.g., Gln).
[0097] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Leu571 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Leu571 is a mutation to a non-polar or hydrophobic amino acid (e.g., Phe, Ile, Met or Trp).
[0098] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu576 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu576 is a mutation to a non-polar or hydrophobic amino acid (e.g., Leu).
[0099] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Glu580 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys or Arg, preferably Lys). In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to a non-polar amino acid (e.g., Ile, Val or Met). In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to a hydrophobic amino acid (e.g., Ile or Val). In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to an uncharged amino acid (e.g., Gln). In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to Arg. In one embodiment, the substitution mutation at a position functionally equivalent to Glu580 is a mutation to Ile. In one embodiment, the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys.
[0100] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Thr590 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Thr590 is a mutation to a polar amino acid (eg, Lys).
[0101] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ala595 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ala595 is a mutation to a non-polar or hydrophobic amino acid (e.g., Met).
[0102] In one embodiment, the altered B family polymerase includes a substitution mutation at a position functionally equivalent to Ile603 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ile603 is a mutation to a polar amino acid (eg, Asp).
[0103] The present disclosure also provides altered B family polymerases having a combination of substitution mutations, including but not limited to those described above. In one or more embodiments, the altered B family polymerase includes substitution mutations at at least two, three, four, five or six positions.
[0104] In one embodiment, the altered polymerase comprises at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys or Arg, preferably Lys). The second substitution mutation is functionally equivalent to the position of Trp516 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Trp516 is a mutation to a non-polar amino acid (e.g., Ile or Met, preferably Met). Alternatively, the second substitution mutation may be functionally equivalent to the position of Trp516 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Trp516 is a mutation to a non-polar or hydrophobic amino acid (e.g., Leu). In one embodiment, the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys, and the substitution mutation at the position functionally equivalent to Trp516 is a mutation to Met or a mutation to Leu.
[0105] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys or Arg, preferably Lys). The second substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (e.g., Ser). In one embodiment, the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys, and the substitution mutation at the position functionally equivalent to Ala408 is a mutation to Ser.
[0106] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid (eg, Met). The second substitution mutation is functionally equivalent to the position of Val485 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Val485 is a mutation to a non-polar, hydrophobic or uncharged amino acid (eg, Gly). In one embodiment, the substitution mutation at the position functionally equivalent to Val485 is a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 is a mutation to Gly.
[0107] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Leu571 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Leu571 is a mutation to a non-polar or hydrophobic amino acid (e.g., Phe, Ile, Met, or Trp). The second substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys, or Arg). In one embodiment, the substitution mutation at the position functionally equivalent to Leu571 is a mutation to Phe, and the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys. In another embodiment, the substitution mutation at the position functionally equivalent to Leu571 is a mutation to Met, and the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Gln.
[0108] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is at a position functionally equivalent to Val485 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at a position functionally equivalent to Val485 is a mutation to a polar amino acid (e.g., Lys, Asn, Gln, Ser, or Thr) or an uncharged amino acid (e.g., Asn, Gly, Gln, Ser, or Thr). The second substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901, wherein the substitution mutation at a position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys, or Arg). In one embodiment, the substitution mutation at a position functionally equivalent to Val485 is a mutation to Thr, and the substitution mutation at a position functionally equivalent to Glu580 is a mutation to Lys.
[0109] In one embodiment, the modified polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Ile410 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (e.g., Val). The second substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys, or Arg). In one embodiment, the substitution mutation at the position functionally equivalent to Ile410 is a mutation to Val, and the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys.
[0110] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid or a hydrophobic amino acid (e.g., Met). The second substitution mutation is functionally equivalent to the position of Ile410 in Pol1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (e.g., Val). In one embodiment, the substitution mutation at the position functionally equivalent to Phe405 is a mutation to Met, and the substitution mutation at the position functionally equivalent to Ile410 is a mutation to Val.
[0111] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe140 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Phe140 is a mutation to a non-polar amino acid or a hydrophobic amino acid (eg, Leu). The second substitution mutation is functionally equivalent to the position of Ser407 in Pol1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Ser407 is a mutation to a non-polar amino acid or a hydrophobic amino acid (eg, Leu). In one embodiment, the substitution mutation at the position functionally equivalent to Phe140 is a mutation to Leu, and the substitution mutation at the position functionally equivalent to Ser407 is a mutation to Leu.
[0112] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid or a hydrophobic amino acid (e.g., Met). The second substitution mutation is functionally equivalent to the position of Glu580 in Pol1901, wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys, or Arg). In one embodiment, the substitution mutation at the position functionally equivalent to Phe405 is a mutation to Met, and the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Arg.
[0113] In one embodiment, the altered polymerase includes at least two substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid or a hydrophobic amino acid (e.g., Met). The second substitution mutation is functionally equivalent to the position of Glu580 in Pol1901, wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys, or Arg). In one embodiment, the substitution mutation at the position functionally equivalent to Phe405 is a mutation to Met, and the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys.
[0114] In one embodiment, the altered polymerase includes at least three substitution mutations. The first substitution mutation is functionally equivalent to the position of Glu580 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Glu580 is a mutation to a polar amino acid (e.g., Gln, Lys or Arg, preferably Lys). The second substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (e.g., Ser). The third substitution mutation is functionally equivalent to the position of Ile410 in Pol1901, wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (e.g., Val). In one embodiment, the substitution mutation at the position functionally equivalent to Glu580 is a mutation to Lys, the substitution mutation at the position functionally equivalent to Ala408 is a mutation to Ser, and the substitution mutation at the position functionally equivalent to Ile410 is a mutation to Val.
[0115] In one embodiment, the altered polymerase includes at least three substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid (e.g., Met). The second substitution mutation is functionally equivalent to the position of Val485 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Val485 is a mutation to a non-polar, hydrophobic, or uncharged amino acid (e.g., Gly). The third substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (e.g., Ser). In one embodiment, the substitution mutation at the position functionally equivalent to Phe405 is a mutation to Met, the substitution mutation at the position functionally equivalent to Val485 is a mutation to Gly, and the substitution mutation at the position functionally equivalent to Ala408 is a mutation to Ser.
[0116] In one embodiment, the altered polymerase includes at least four substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar amino acid (eg, Met). The second substitution mutation is functionally equivalent to the position of Val485 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Val485 is a mutation to a non-polar, hydrophobic or uncharged amino acid (eg, Gly). The third substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (eg, Ser). The fourth substitution mutation is at a position functionally equivalent to Ile410 in Pol 1901, wherein the substitution mutation at a position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (eg, Val).
[0117] In one embodiment, the altered polymerase includes at least four substitution mutations. The first substitution mutation is functionally equivalent to the position of Leu403 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Leu403 is a mutation to a non-polar amino acid (eg, Met). The second substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (eg, Ser). The third substitution mutation is functionally equivalent to the position of Ile410 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (eg, Val). The fourth substitution mutation is functionally equivalent to the position of Gly497 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Gly497 is a mutation to a non-polar amino acid (eg, Met). In one embodiment, the substitution mutation at the position functionally equivalent to Leu403 is a mutation to Met, the substitution mutation at the position functionally equivalent to Ala408 is a mutation to Ser, the substitution mutation at the position functionally equivalent to Ile410 is a mutation to Val, and the substitution mutation at the position functionally equivalent to Gly497 is a mutation to Met.
[0118] In one embodiment, the altered polymerase includes at least five substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ile). The second substitution mutation is functionally equivalent to the position of Ile410 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (e.g., Pro). The third substitution mutation is functionally equivalent to the position of Ile412 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ile412 is a mutation to a non-polar amino acid (e.g., Met). The fourth substitution mutation is functionally equivalent to the position of Thr514 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Thr514 is a mutation to a non-polar or hydrophobic amino acid (eg, Ala). The fifth substitution mutation is functionally equivalent to the position of Ile521 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Ile521 is a mutation to a non-polar or hydrophobic amino acid (eg, Ala). In one embodiment, the substitution mutation at the position functionally equivalent to Phe405 is a mutation to Ile, the substitution mutation at the position functionally equivalent to Ile410 is a mutation to Pro, the substitution mutation at the position functionally equivalent to Ile412 is a mutation to Met, the substitution mutation at the position functionally equivalent to Thr514 is a mutation to Ala, and the substitution mutation at the position functionally equivalent to Ile521 is a mutation to Ala.
[0119] In one embodiment, the altered polymerase includes at least four substitution mutations. The first substitution mutation is functionally equivalent to the position of Phe405 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Phe405 is a mutation to a non-polar or hydrophobic amino acid (e.g., Leu). The second substitution mutation is functionally equivalent to the position of Ala408 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ala408 is a mutation to a polar or uncharged amino acid (e.g., Ser). The third substitution mutation is functionally equivalent to the position of Ile410 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ile410 is a mutation to a non-polar or hydrophobic amino acid (e.g., Val). The fourth substitution mutation is functionally equivalent to the position of Ile412 in Pol 1901, wherein the substitution mutation at the position functionally equivalent to Ile412 is a mutation to a polar or uncharged amino acid (e.g., Thr). The fifth substitution mutation is functionally equivalent to the position of Thr514 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Thr514 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ala). The sixth substitution mutation is functionally equivalent to the position of Ile521 in Pol 1901 (SEQ ID NO: 1), wherein the substitution mutation at the position functionally equivalent to Ile521 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ala). In one embodiment, the substitution mutation at a position functionally equivalent to Phe405 is a mutation to Leu, the substitution mutation at a position functionally equivalent to Ala408 is a mutation to Ser, the substitution mutation at a position functionally equivalent to Ile410 is a mutation to Val, the substitution mutation at a position functionally equivalent to Ile412 is a mutation to Thr, the substitution mutation at a position functionally equivalent to Thr514 is a mutation to Ala, and the substitution mutation at a position functionally equivalent to Ile521 is a mutation to Ala.
[0120] In one or more embodiments, the modified B family type polymerase of the present disclosure may include additional substitution mutations. For example, the polymerase described herein with one or more substitution mutations may also include one or more substitution mutations at positions functionally equivalent to Lys349, Ala281, Trp397 or Gly633 in Pol1901.
[0121] In one embodiment, the altered B family polymerase optionally includes a substitution mutation at a position functionally equivalent to Lys349 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Lys349 is a mutation to a polar or uncharged amino acid (e.g., Asn or Ser).
[0122] In one embodiment, the altered B family polymerase optionally includes a substitution mutation at a position functionally equivalent to Ala281 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Ala281 is a mutation to a non-polar or hydrophobic amino acid (e.g., Gly or Phe). In one embodiment, the substitution mutation at a position functionally equivalent to Ala281 is a mutation to an uncharged amino acid (e.g., Gly).
[0123] In one embodiment, the altered B family polymerase optionally includes a substitution mutation at a position functionally equivalent to Phe283 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Phe283 is a mutation to a polar or uncharged amino acid (e.g., Ser).
[0124] In one embodiment, the altered B family polymerase optionally includes a substitution mutation at a position functionally equivalent to Trp397 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Trp397 is a mutation to a polar or uncharged amino acid (e.g., Cys). In one embodiment, the substitution mutation at a position functionally equivalent to Trp397 is a mutation to a non-polar or hydrophobic amino acid (e.g., Phe).
[0125] In one embodiment, the altered B family polymerase optionally includes a substitution mutation at a position functionally equivalent to Gly633 in Pol 1901 (SEQ ID NO: 1). In one embodiment, the substitution mutation at a position functionally equivalent to Gly633 is a mutation to a polar or uncharged amino acid (e.g., Thr).
[0126] Specific examples of the altered polymerase include polymerases disclosed in SEQ ID NO:2 to SEQ ID NO:32.
[0127] The modified polymerase described herein may include additional mutations known to affect polymerase activity. Such substitution mutations are functionally equivalent to the position of Arg713 in Pol 1901 (SEQ ID NO: 1). Any of a variety of substitution mutations may be performed at one or more positions in the position known to cause reduced exonuclease activity, as known in the art and illustrated by U.S. Patent No. 8,623,628. In one embodiment, the substitution mutation at position Arg713 is a mutation to non-polar, hydrophobic or uncharged amino acids (e.g., Gly, Met or Ala).
[0128] In one embodiment, the altered polymerase includes a substitution mutation at a position functionally equivalent to Arg743 or Lys705 or a combination thereof in Pol 1901 (SEQ ID NO: 1), as known in the art and exemplified by the disclosure of U.S. Pat. No. 8,623,628. In one embodiment, the substitution mutation at position Arg743 or Lys705 is a mutation to a non-polar or hydrophobic amino acid (e.g., Ala).
[0129] Second Generation ffN
[0130] The polymerases of the present disclosure can be used with modified nucleotides. The modified nucleotides typically include a modification at the 3'-OH of the nucleotide sugar moiety, a detectable label attached to the base via a cleavable linker, or both a 3'-OH modification and a detectable label attached to the base via a cleavable linker.
[0131] In one or more embodiments, the second generation FFN described herein comprises or has a structure of formula (I):
[0132]
[0133] Wherein B is a nucleobase; R4 is OH; R5 is H or a 3'-OH capping group; R6 is H, a monophosphate, a diphosphate, a triphosphate, a thiophosphate, a phosphate analog, a reactive phosphorus-containing group or a hydroxyl protecting group; R7 is H or a L1-L-L2-label (U.S. Published Patent Application 2021 / 0403500).
[0134] Nucleobases can be purines or pyrimidines. Examples of pyrimidines include cytosine (C) and thymine (T), 5,6-dihydrouracil and 5-alkylcytosine (e.g., 5-methylcytosine). Examples of purines include adenine (A) and guanine (G) and optionally substituted purine bases such as deazapurines, adenine, 7-deazaadenine, guanine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid and isoguanine.
[0135] The label is a detectable label. Useful detectable labels are known in the art and include, but are not limited to, fluorophores, such as fluorescent dyes.
[0136] L is a cleavable linker And any one of L1 and L2 is independently an optionally present linker moiety.
[0137] In some embodiments of the cleavable linker moiety, each of X and Y is O. In some other embodiments, X is S and Y is O, or X is O and Y is S. In some embodiments, each of R1a, R1b, R2, R3a and R3b is H. In other embodiments, at least one of R1a, R1b, R2, R3a and R3b is halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). In some such cases, each of R1a and R1b is H, and each of R2, R3a and R3b is unsubstituted C1-C6 alkyl or halogen (e.g., R2 is unsubstituted C1-C6 alkyl, and each of R3a and R3b is H; or R2 is H, and one or both of R3a and R3b are halogen or unsubstituted C1-C6 alkyl). In one embodiment, the cleavable linker L comprises
[0138]
[0139] (“AOL” connector portion).
[0140] The wavy line refers to the connection of the cleavable linker L to the optional L1 and L2 or the connection of the cleavable linker L (in the absence of L1 and / or L2) to the nucleobase and / or the detectable label. In one or more embodiments, the connection of the optional L1 or L2 or the connection of the cleavable linker L (in the absence of L1 and / or L2) to the nucleobase is located at the C5 position of the pyrimidine base or the C7 position of the purine base. In one or more embodiments, L1-L-L2 is selected from
[0141]
[0142] wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the nucleobase; and ** indicates the point of attachment of the cleavable linker to the detectable label.
[0143] Useful modifications at the 3'-OH of the nucleotide sugar moiety are known in the art, such as a 3'-O-azidomethyl capping group -CH2N3. In one or more embodiments, the polymerase disclosed herein is used with modified nucleotides having a 3'-OH acetal capping group or a 3'-OH thiocarbamate capping group (U.S. Pat. No. 11,293,061; U.S. Application Serial No. 17 / 748,498).
[0144] Examples of 3'-hydroxyacetal capping groups attached to a nucleotide having a deoxyribose sugar with a removable 3'-OH capping group include those forming the structure
[0145]
[0146] This structure is covalently linked to the 3'-carbon atom where:
[0147] R 1a and R 1b Each independently represents H, C1-C6 alkyl, C 1- C6 haloalkyl, C 1- C6 alkoxy, C 1- C6 haloalkoxy, cyano, halogen, optionally substituted phenyl or optionally substituted aralkyl;
[0148] R 2a and R 2b Each independently is H, C 1- C6 alkyl, C 1- C6 haloalkyl, cyano or halogen;
[0149] Alternatively, R1a and R2a together with the atoms to which they are attached form an optionally substituted five to eight membered heterocyclyl group;
[0150] R 3 is H, optionally substituted C 2- C6 alkenyl, optionally substituted C 3- C7 cycloalkenyl, optionally substituted C 2- C6 alkynyl or optionally substituted (C 1- C6 alkylene)Si(R 4 )3; and
[0151] Each R 4 Independently H, C 1- C6 alkyl or optionally substituted C 6- C10 Aryl; provided that when each R 1a , R 1b , R 2a and R 2b When H, R 3 is not H (all technical and scientific terms regarding 3'-hydroxyacetal end-capping groups are defined in U.S. Pat. No. 11,293,061). In one or more embodiments, the 3'-hydroxyacetal end-capping group has the structure
[0152]
[0153] ("AOM" 3' blocking group).
[0154] The wavy line refers to the attachment of the oxygen to the 3' carbon of the nucleotide sugar.
[0155] Examples of 3'-hydroxyacetal capping groups attached to a nucleotide having a removable 3'-OH capping group include those forming the structure
[0156]
[0157] This structure is covalently linked to the 3'-carbon atom where:
[0158] R 5 and R 6 Each of which is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C8 alkoxyalkyl, optionally substituted —(CH2) m -phenyl, optionally substituted-(CH2) n -(5 or 6 membered heteroaryl), optionally substituted-(CH2) k —C3-C7 carbocyclyl, or optionally substituted —(CH2) p -(3 to 7 membered heterocyclyl);
[0159] Alternatively, R 5 and R 6 together with the atoms to which they are attached form an optionally substituted five- to seven-membered heterocyclyl;
[0160] —(CH2) m —, —(CH2) n —, —(CH2) k —and—(CH2) p — is optionally substituted; and any of m, n, k and p is independently 0, 1, 2, 3 or 4 (all technical and scientific terms regarding 3'-hydroxythiocarbamate end-capping groups are defined in US Pat. No. 11,293,061).
[0161] Non-limiting examples of second generation FFNs that can be used with the altered polymerases of the present disclosure include, but are not limited to, those having Formula (Ia), (Ia'), (Ib), (Ic), (Ic'), or (Id):
[0162]
[0163]
[0164]
[0165] wherein R4 is OH, and wherein R6 is H, a monophosphate, a diphosphate, a triphosphate, a thiophosphate, a phosphate analog, a reactive phosphorus-containing group, or a hydroxyl protecting group.
[0166] The methods disclosed herein include using second generation ffN to synthesize polynucleotides (U.S. Published Patent Application 2021 / 0403500; U.S. Application Serial No. 17 / 748,498). Examples of polynucleotides including nucleotides of formula (Ia') include the following structures:
[0167]
[0168] Non-limiting examples of label conjugates (such as fluorescent dye conjugates) include those having the following structures:
[0169]
[0170]
[0171] wherein PG represents a 3'-OH end-capping group as described in U.S. Published Patent Application 2021 / 0403500; n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and k is 0, 1, 2, 3, 4, or 5. In one embodiment, -O-PG is AOM. In another embodiment, -O-PG is -O-azidomethyl. In one embodiment, n is 5.
[0172] Mutant polymerase
[0173] Various types of mutagenesis are optionally used in the present disclosure, for example, according to the polymerase model discussed herein and model prediction or using random or semi-random mutation method to modify polymerase, for example, to produce variants. Generally, any available mutagenesis program can be used to prepare polymerase mutants. Such mutagenesis program optionally includes selecting mutant nucleic acids and polypeptides for one or more activities of interest (for example, for second generation WN, lower error rate, lower phasing rate or increased incorporation rate). The program that can be used includes but is not limited to: site-directed point mutagenesis, random point mutagenesis, homologous recombination (DNA reorganization and combined overlapping PCR) in vitro or in vivo, mutagenesis using a template containing uracil, oligonucleotide-directed mutagenesis, thiophosphate-modified DNA mutagenesis, mutagenesis using gap duplex DNA, point mispairing repair, mutagenesis using repair defective host strain, restricted selection and restricted purification, deletion mutagenesis, full gene synthesis mutagenesis, degenerate PCR, double-strand break repair and many other programs known to technicians. The starting polymerase used for mutation can be any of those reference polymerases mentioned herein, including useful polymerase mutants such as those identified in, for example, U.S. Pat. No. 8,460,910, U.S. Pat. No. 8,623,628, U.S. Pat. No. 10,421,996, U.S. Pat. No. 9,765,309, U.S. Pat. No. 9,677,057, U.S. Pat. No. 11,104,888, U.S. Pat. No. 11,001,816.
[0174] Optionally, mutagenesis can be guided by known information from naturally occurring polymerase molecules or known altered or mutant polymerases (e.g., using existing mutant polymerases), such as sequence, sequence comparisons, physical properties, crystal structure, etc. discussed above. However, in another class of embodiments, modifications can be essentially random (e.g., as in classical or "family" DNA shuffling, see, e.g., Crameri et al. (1998) "DNA shuffling of a family of genes from diverse species accelerates directed evolution" Nature 391: 288-291).
[0175] Additional information on mutation formats can be found in Sambrook et al., Molecular Cloning—A Laboratory Manual (3rd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 2000 (“Sambrook”); Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2011) (“Ausubel”)) and PCR Protocols A Guide to Methods and Applications (Innis et al., eds.) Academic Press Inc. San Diego, Calif. (1990) (“Innis”). The following cited publications and references provide additional details on mutagenesis formats: Arnold, Protein engineering for unusual environments, Current Opinion in Biotechnology 4:450-455 (1993); Bass et al., Mutant Trprepressors with new DNA-binding specificities, Science 242:240-245 (1988); Bordo and Argos (1991) Suggestions for "Safe" Residue Substitutions in Site-directed Mutagenesis 217:721-729; Botstein and Shortle, Strategies and applications of invitro mutagenesis, Science 229:1193-1201 (1985); Carter et al., Improved oligonucleotide site-directed mutagenesis using M13 vectors, Nucl. Acids Res.13:4431-4443(1985); Carter, Site-directed mutagenesis, Biochem. J. 237:1-7(1986); Carter, Improved oligonucleotide-directed mutagenesis using M13 vectors, Methods in Enzymol. 154:382-403(1987); Dale et al., Oligonucleotide-directed random mutagenesis using the phosphorothioate method, Methods Mol. Biol. 57:369-374(1996); Eghtedarzadeh and Henikoff, Use of oligonucleotides to generate large deletions, Nucl. Acids Res. 14:5115(1986); Fritz et al., Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro, Nucl. Acids Res. 16:6987-6999(1988); Grundstrom et al., Oligonucleotide-directed mutagenesis by microscale'shot-gun' gene synthesis, Nucl. Acids Res. 13:3305-3316(1985); Hayes(2002)Combining Computational and Experimental Screening for rapid Optimization of Protein Properties PNAS 99(25)15926-15931; Kunkel, The efficiency of oligonucleotide directed mutagenesis, in Nucleic Acids & Molecular Biology (Eckstein, F. and Lilley, D.M.J.Editor, Springer Verlag, Berlin)) (1987); Kunkel, Rapid and efficient site-specific mutagenesis without phenotypic selection, Proc. Natl. Acad. Sci. USA 82: 488-492 (1985); Kunkel et al., Rapid and efficient site-specific mutagenesis without phenotypic selection, Methods in Enzymol. 154, 367-382 (1987); Kramer et al., The gapped duplex DNA approach to oligonucleotide-directed mutation construction, Nucl. Acids Res. 12: 9441-9456 (1984); Kramer and Fritz Oligonucleotide-directed construction of mutations via gapped duplex DNA, Methods in Enzymol. 154: 350-367 (1987); Kramer et al., Point Mismatch Repair, Cell 38: 879-887 (1984); Kramer et al., Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations, Nucl. Acids Res. 16: 7207 (1988); Ling et al., Approaches to DNA mutagenesis: an overview, Anal Biochem. 254(2): 157-178 (1997); Lorimer and Pastan Nucleic Acids Res.23,3067-8(1995); Mandecki, Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis, Proc. Natl. Acad. Sci. USA, 83:7177-7181(1986); Nakamaye and Eckstein, Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis, Nucl. Acids Res. 14:9679-9698(1986); Nambiar et al., Total synthesis and cloning of a gene coding for the ribonuclease S protein, Science 223:1299-1301(1984); Sakamar and Khorana, Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14:6361-6372(1988); Sayers et al., Y-T Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis, Nucl. Acids Res. 16:791-802(1988); Sayers et al., Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide, (1988) Nucl. Acids Res.16:803-814; Sieber et al., Nature Biotechnology, 19:456-460 (2001); Smith, In vitro mutagenesis, Ann. Rev. Genet. 19:423-462 (1985); Methods in Enzymol. 100:468-500 (1983); Methods in Enzymol. 154:329-350 (1987); Stemmer, Nature 370, 389-91 (1994); Taylor et al., The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA, Nucl. Acids Res. 13:8749-8764 (1985); Taylor et al., The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA, Nucl. Acids Res. 13:8765-8787 (1985); Wells et al., Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin, Phil. Trans. R. Soc. Lond. A 317:415-423 (1986); Wells et al., Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites, Gene 34:315-323 (1985); Zoller and Smith, Oligonucleotide-directed mutagenesis using M 13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment, Nucleic Acids Res.10:6487-6500(1982); Zoller and Smith, Oligonucleotide-directed mutagenesis of DNAfragments cloned into M13 vectors, Methods in Enzymol.100:468-500(1983); inEnzymol.154:329-350(1987); Clackson et al. (1991) "Making antibody fragments using phage display libraries" Nature 352:624-628; Gibbs et al. (2001) "Degenerateoligonucleotide gene shuffling (DOGS): a method for enhancing the frequency of recombination with family shuffling" Gene 271:13-20; and Hiraga and Arnold (2003) "General method for sequence-independent site-directed chimeragenesis: J. Mol. Biol. 330:287-296. Additional details on many of the above methods can be found in Methods in Enzymology, volume 154, which also describes useful controls for troubleshooting problems with various mutagenesis methods.
[0176] Preparation and isolation of recombinant polymerase
[0177] Generally, nucleic acid encoding the polymerase provided by this paper can be prepared by cloning, recombination, in vitro synthesis, in vitro amplification and / or other available methods, or obtained from commercial suppliers. A variety of recombinant methods can be used to express the expression vector encoding the polymerase disclosed herein. Methods for preparing recombinant nucleic acids, expressing and separating expression products are well known in the art and described. Many exemplary mutations and combinations of mutations and strategies for designing desired mutations are described herein. In this article and for example in WO 2007 / 076057 and WO 2008 / 051530, methods for making and selecting mutations in the active site of the polymerase are found, including for modifying the spatial characteristics in or near the active site to allow improved access to modified nucleotides.
[0178] Additional useful references for mutagenesis, recombination, and in vitro nucleic acid manipulation methods (including cloning, expression, PCR, etc.) include Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology Vol. 152 Academic Press, Inc., San Diego, Calif. (Berger); Kaufman et al. (2003) Handbook of Molecular and Cellular Methods in Biology and Medicine 2nd Edition Ceske (ed.) CRC Press (Kaufman); The Nucleic Acid Protocols Handbook Ralph Rapley (ed.) (2000) Cold Spring Harbor, Humana Press Inc (Rapley); Chen et al. (eds.) PCR Cloning Protocols, 2nd Edition (Methods in Molecular Biology, Vol. 192) Humana Press; and Viljoen et al. (2005) Molecular Diagnostic PCR Handbook Springer, ISBN 1402034032.
[0179] In addition, many kits are commercially available for purification of plasmids or other relevant nucleic acids from cells (see, for example, StrataClean from Stratagene). TM ; QIAprep from Qiagen TM. ) Any isolated and / or purified nucleic acid can be further manipulated to produce other nucleic acids, used for transfecting cells, incorporated into related vectors to infect organisms for expression, etc. Typical cloning vectors contain transcription and translation terminators, transcription and translation initiation sequences, and promoters that can be used to regulate the expression of specific target nucleic acids. The vector optionally comprises a universal expression cassette that contains at least one independent terminator sequence, a sequence that allows the replication of the cassette in eukaryotes or prokaryotes or both (e.g., a shuttle vector), and selection markers for both prokaryotic and eukaryotic systems. The vector is suitable for replication and integration in prokaryotes, eukaryotes, or both.
[0180] Other useful references, e.g., for cell isolation and culture (e.g., for subsequent nucleic acid isolation), include Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, 3rd Edition, Wiley-Liss, New York, and references cited therein; Payne et al. (1992) Plant Cell and Tissue Culture in Liquid Systems John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds.) (1995) Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York); and Atlas and Parks (eds.) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, Fla. Standard ligation techniques known in the art are used to construct vectors containing nucleic acids encoding the altered polymerases described herein. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual., Cold Spring Harbor Laboratory Press (1989) or Ausubel, RM, ed., Current Protocols in Molecular Biology (1994).
[0181] The present disclosure also includes nucleic acids encoding the changed polymerase disclosed herein.Specific amino acids can be encoded by multiple codons, and some translation systems (e.g., prokaryotic cells or eukaryotic cells) often show codon biases, for example, different organisms often preferably encode one of several synonymous codons of the same amino acid.Therefore, nucleic acids as provided herein are optionally "codon optimized," which means that synthetic nucleic acids are to include the preferred codons of a specific translation system for expressing polymerase.For example, when it is desired to express polymerase in bacterial cells (or even specific bacterial strains), synthetic nucleic acids can be included in the most common codons in the genome of the bacterial cells for effective expression of polymerase.When it is desired to express polymerase in eukaryotic cells, similar strategies can be adopted, for example, nucleic acids can include the preferred codons of the eukaryotic cells.
[0182] A variety of protein isolation and detection methods are known and can be used to isolate a polymerase (eg, from a recombinant culture of cells expressing a recombinant polymerase provided herein). A variety of protein separation and detection methods are well known in the art, and include, for example, those described in the following references: R. Scopes, Protein Purification, Springer-Verlag, NY (1982); Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification, Academic Press, Inc. NY (1990); Sandana (1997) Bioseparation of Proteins, Academic Press, Inc.; Bollag et al. (1996) Protein Methods, 2nd Edition Wiley-Liss, NY; Walker (1996) The Protein Protocols Handbook Humana Press, NJ, Harris and Angal (1990) Protein Purification Applications: A Practical Approach IRL Press at Oxford, Oxford, England; Harris and Angal Protein Purification Methods: A Practical Approach IRL Press at Oxford, Oxford, England; Scopes (1993) Protein Purification: Principles and Practice 3rd Edition Springer Verlag, NY; Janson and Ryden (1998) Protein Purification: Principles, High Resolution Methods and Applications, 2nd Edition Wiley-VCH, NY; and Walker (1998) Protein Protocols on CD-ROM Humana Press, NJ; and references cited therein. Additional details on protein purification and detection methods can be found in Satinder Ahuja, ed., Handbook of Bioseparations, Academic Press (2000).
[0183] How to use
[0184] The modified polymerase provided herein can be used for sequencing procedures, such as sequencing by synthesis (SBS) technology. In short, SBS can be initiated by contacting the target nucleic acid with one or more nucleotides (e.g., labeled, synthetic, modified nucleotides or combinations thereof), DNA polymerases, etc. The features of using the target nucleic acid as a template to extend the primer will incorporate the nucleotides of the marker that can be detected. Using the modified polymerase described herein can produce a lower error rate, a lower phasing rate, a lower pre-phasing or an increased incorporation rate (i.e., a shortened incorporation time) in a sequencing run. In one or more embodiments, the labeled nucleotides can also be modified, for example, also including a reversible termination property that terminates further primer extension once the nucleotides are added to the primer. For example, a modified nucleotide with a reversible terminator portion can be added to the primer so that subsequent extension does not occur until a deblocking agent is delivered to remove the portion. In one or more embodiments, the reversible terminator portion includes a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group. Therefore, for the embodiment using reversible termination, the deblocking reagent can be delivered to the circulation pool (before or after detection occurs). Washing can be performed between each delivery step. The cycle can then be repeated n times to extend the primer by n nucleotides, so as to detect a sequence of length n. The exemplary SBS program, fluid system and detection platform that can be easily adapted to be used with the array produced by the method of the present disclosure are described in, for example, the following documents: Bentley et al., Nature 456:53-59 (2008); WO 04 / 018497; WO 91 / 06678; WO 07 / 123744; U.S. Patent No. 7,057,026, U.S. Patent No. 7,329,492, U.S. Patent No. 7,211,414, U.S. Patent No. 7,315,019, U.S. Patent No. 7,405,281 and U.S. Patent No. 8,343,746.
[0185] Other sequencing procedures using cyclic reactions can be used, such as pyrophosphate sequencing. Pyrophosphate sequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into a nascent nucleic acid chain (Ronaghi et al., Analytical Biochemistry 242 (1), 84-9 (1996); Ronaghi, Genome Res. 11 (1), 3-11 (2001); Ronaghi et al., Science 281 (5375), 363 (1998); U.S. Patent No. 6,210,891; No. 6,258,568 and No. 6,274,320). In pyrophosphate sequencing, the released PPi can be detected by converting it into adenosine triphosphate (ATP) by ATP sulfurylase, and the resulting ATP can be detected via photons generated by luciferase. Therefore, the sequencing reaction can be monitored via a luminescent detection system. The excitation radiation source for the fluorescence-based detection system is not necessary for the pyrophosphate sequencing procedure. Useful fluidic systems, detectors, and procedures that can be used to apply pyrosequencing to the arrays of the present disclosure are described in, for example, WO 2012 / 058096, US Patent Application Publication No. 2005 / 0191698 Al, US Patent No. 7,595,883, and US Patent No. 7,244,559.
[0186] Some embodiments may use methods involving real-time monitoring of DNA polymerase activity. For example, nucleotide incorporation may be detected by fluorescence resonance energy transfer (FRET) interactions between a polymerase carrying a fluorophore and a γ-phosphate labeled nucleotide or by using a zero-mode waveguide. Techniques and reagents for FRET-based sequencing are described, for example, in Levene et al., Science 299, 682-686 (2003); Lundquist et al., Opt. Lett. 33, 1026-1028 (2008); Korlach et al., Proc. Natl. Acad. Sci. USA 105, 1176-1181 (2008).
[0187] Some SBS embodiments include detecting protons released when nucleotides are incorporated into extension products. For example, sequencing based on detection of released protons can use electrical detectors and related technologies commercially available from Ion Torrent (Thermo Fisher Scientific) or sequencing methods and systems described in U.S. Pat. No. 8,262,900, U.S. Pat. No. 7,948,015, U.S. Pat. No. 8,349,167, and U.S. Published Patent Application No. 2010 / 0137143A1.
[0188] Therefore, the present invention provides a method for incorporating modified nucleotides into DNA, which method includes allowing the following components to interact: (i) a modified polymerase as described herein; (ii) a DNA template; and (iii) a nucleotide solution. In certain embodiments, the DNA template can be associated with an array, which includes a clustered array. The DNA template can be double-stranded or single-stranded. In one or more embodiments, the nucleotide is a modified nucleotide, such as a second generation WN as described herein. The modified nucleotide generally includes a modification at the 3'-OH of the nucleotide sugar moiety, a detectable label connected to a base via a cleavable joint, or a 3'-OH modification and a detectable label connected to a base via a cleavable joint.
[0189] Nucleic acid encoding an altered polymerase
[0190] The present disclosure also includes nucleic acid molecules encoding the altered polymerases described herein. For any given altered polymerase (the altered polymerase is an amino acid sequence, and preferably, a wild-type nucleotide sequence encoding the polymerase) a known mutant form of the polymerase, it is possible to obtain the nucleotide sequence encoding the mutant according to the basic principles of molecular biology. For example, assuming that the wild-type nucleotide sequence encoding the 9°N polymerase is known, the standard genetic code can be used to deduce the nucleotide sequence encoding any given mutant version of 9°N having one or more amino acid substitutions. Similarly, for other mutant forms of polymerases, such as, for example Polymerase, Deep Polymerase, Pfu polymerase, KOD polymerase, Pab polymerase, etc., can be used to easily obtain the nucleotide sequence. Then, standard molecular biology techniques known in the art can be used to construct nucleic acid molecules with the desired nucleotide sequence.
[0191] According to the embodiments provided herein, the defined nucleic acids include not only identical nucleic acids, but also any minor base changes, which specifically include substitutions in the case of synonymous codons (different codons that specify the same amino acid residue) due to degenerate codes in conservative amino acid substitutions. The class of nucleotide sequences encoding the altered polymerases disclosed herein is large but finite, and the nucleotide sequence of each member of the class can be easily determined by reference to the standard genetic code.
[0192] The term "nucleic acid sequence" also includes the complementary sequence to any single-stranded sequence given with respect to base changes and the corresponding RNA sequence.
[0193] The nucleic acid molecules described herein can also be advantageously included in suitable expression vectors to express the altered polymerase protein encoded therein in suitable hosts. Incorporation of cloned DNA into suitable expression vectors for subsequent transformation of the cells and subsequent selection of transformed cells is well known to those skilled in the art, as provided in Sambrook et al. (1989), Molecular cloning: A Laboratory Manual, Cold Spring Harbor Laboratory.
[0194] Such expression vectors include vectors with nucleic acids according to the embodiments provided herein, which are effectively connected to regulatory sequences capable of realizing the expression of the DNA fragments, such as promoter regions. The term "operably connected" refers to the juxtaposition of components described therein in a relationship that allows them to function in their intended manner. Such vectors can be converted into suitable host cells to provide protein expression according to the embodiments provided herein.
[0195] The nucleic acid molecule can encode a mature protein or a protein with a presequence, including a nucleic acid encoding a leader sequence on a preprotein, which is then cleaved by the host cell to form a mature protein. The vector can be, for example, a plasmid, a virus or a phage vector, which is provided with a replication origin, and optionally a promoter for expressing the nucleotide and optionally a regulator of the promoter. The vector can contain one or more selective markers, such as, for example, an antibiotic resistance gene.
[0196] The regulatory elements required for expression include promoter sequences for binding RNA polymerase and guiding the initiation of transcription at an appropriate level, and translation initiation sequences for ribosome binding. For example, bacterial expression vectors can include promoters, such as lac promoters, and Shine-dalarno sequences and start codon AUG for translation initiation. Similarly, eukaryotic expression vectors can include heterologous or homologous promoters for RNA polymerase II, downstream polyadenylation signals, start codon AUG and stop codons for separating ribosomes. Such vectors can be commercially available or assembled by sequences described by methods well known in the art.
[0197] The transcription of DNA encoding polymerase by higher eukaryotic organisms can be optimized by including an enhancer sequence in the vector. An enhancer is a cis-acting element of DNA that acts on a promoter to increase the level of transcription. The vector typically also includes an origin of replication in addition to the selectable marker.
[0198] Reagent test kit
[0199] The present disclosure also provides a kit for performing a nucleotide incorporation reaction. The kit includes at least one modified polymerase described herein and a nucleotide solution in a suitable packaging material, the amount of which is sufficient to perform at least one nucleotide incorporation reaction. Optionally, other reagents required for the use of the modified polymerase and nucleotide solution, such as buffers and solutions, are also included. Examples of other reagents include those suitable for use with second-generation ffN deblocking reagents, palladium catalysts, palladium scavengers, etc. (U.S. Publication Patent Application 2021 / 0403500; U.S. Application Serial No. 17 / 748,498). Instructions for use of the packaging assembly are also included.
[0200] In certain embodiments, nucleotide solution includes the nucleotide of labeling.In certain embodiments, nucleotide is synthetic nucleotide.In certain embodiments, nucleotide is modified nucleotide, such as second generation WN.In certain embodiments, modified nucleotide is modified at 3' sugar hydroxyl place, makes substituent larger than naturally occurring 3' hydroxyl in size.In certain embodiments, modified nucleotide includes modified nucleotide molecule, and this modified nucleotide molecule includes purine or pyrimidine base and deoxyribose moiety, and this deoxyribose moiety has removable 3'-OH end-capping group covalently attached thereto.In one or more embodiments, 3' carbon atom is connected with 3'-OH acetal end-capping group or 3'-OH thiocarbamate end-capping group.3'-OH acetal end-capping group and 3'-OH thiocarbamate end-capping group are described herein.In one or more embodiments, 3'-hydroxy acetal end-capping group has following structure.
[0201]
[0202] In certain embodiments, the modified nucleotides are fluorescently labeled to allow their detection. In certain embodiments, the modified nucleotides include nucleotides having a base connected to a detectable label via a cleavable linker. In certain embodiments, the detectable label includes a fluorescent label. In certain embodiments, the cleavable linker has the structure
[0203]
[0204] As used herein, the phrase "packaging material" refers to one or more physical structures for containing the contents of the test kit. The packaging material is constructed by known methods and is preferably used to provide a sterile, contaminant-free environment. The packaging material has a mark indicating that these components can be used to perform a nucleotide incorporation reaction. In addition, the packaging material may contain instructions for how to use the materials in the test kit to perform a nucleotide incorporation reaction. As used herein, the term "packaging" refers to a solid matrix or material such as glass, plastic, paper, foil, etc., which can accommodate polypeptides within a fixed range. "Instructions for use" generally include a tangible expression describing the concentration of a reagent or at least one assay method parameter, such as the relative amounts of the reagent to be mixed and the sample, the maintenance time period of the reagent / sample mixture, temperature, buffer conditions, etc.
[0205] Composition
[0206] The present disclosure also provides compositions comprising the changed polymerase as described herein.Except the changed polymerase, the compositions may also include other components.For example, the compositions may include buffer, nucleotide solution, or a combination thereof.The nucleotide solution may include nucleotides, such as labeled nucleotides, synthetic nucleotides, modified nucleotides, or a combination thereof.In one embodiment, the compositions include target nucleic acids, such as a target nucleic acid library.In one embodiment, the compositions may include a changed polymerase present with an array, such as a flow cell or a bead.
[0207] The invention is defined in the claims. However, a non-exhaustive list of non-limiting exemplary aspects is provided below. Any one or more of the features of these aspects may be combined with any one or more features of another example, embodiment or aspect described herein.
[0208] Exemplary Aspects
[0209] Aspect 1 is an altered archaeal B family DNA polymerase, wherein the altered archaeal B family DNA polymerase comprises an amino acid substitution mutation at a position functionally equivalent to an amino acid in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1; wherein the amino acid is at position Arg58 and comprises a mutation to Leu; wherein the amino acid is at position Tyr261 and comprises a mutation to Gly; wherein the amino acid is at position Asn269 and comprises a mutation to Gly or Val; wherein the amino acid is at position Phe283 and comprises a mutation to Ile or L wherein the amino acid is at position Pro328 and comprises a mutation to Asp; wherein the amino acid is at position Met329 and comprises a mutation to Thr; wherein the amino acid is at position Gln332 and comprises a mutation to Ser; wherein the amino acid is at position Leu333 and comprises a mutation to His or Ile; wherein the amino acid is at position Ser347 and comprises a mutation to Asp or Arg or Glu or Val or Thr; wherein the amino acid is at position Asn399 and comprises a mutation to Met or Ala; wherein the amino acid is at position Phe4 wherein the amino acid is at position Glu458 and comprises a mutation to Gly; wherein the amino acid is at position Glu459 and comprises a mutation to Thr or Asp; wherein the amino acid is at position Gln461 and comprises a mutation to Trp; wherein the amino acid is at position Ala469 and comprises a mutation to Trp; wherein the amino acid is at position Ile410 and comprises a mutation to Val; wherein the amino acid is at position Ile412 and comprises a mutation to Val; ... and comprises a mutation to Glu; wherein the amino acid is at position Tyr481 and comprises a mutation to Ile; wherein the amino acid is at position Val485 and comprises a mutation to Asn or Gly or Met or Gln or Ser or Thr; wherein the amino acid is at position Ile486 and comprises a mutation to Leu; wherein the amino acid is at position Trp504 and comprises a mutation to Asn; wherein the amino acid is at position Lys507 and comprises a mutation to His or Pro; wherein the amino acid is at position Glu511 and comprises a mutation to Lys or Met or Arg;wherein the amino acid is at position Trp516 and comprises a mutation to Ile or Lys or Met or Gln or Leu; wherein the amino acid is at position Tyr520 and comprises a mutation to Ala; wherein the amino acid is at position Ile521 and comprises a mutation to Thr; wherein the amino acid is at position Met523 and comprises a mutation to Ile or Thr; wherein the amino acid is at position Arg526 and comprises a mutation to Asn; wherein the amino acid is at position Glu527 and comprises a mutation to Ile; wherein the amino acid is at position Leu528 and comprises a mutation to Thr; wherein the amino acid is at position Ile567 and comprises a mutation to Leu wherein the amino acid is at position Asn568 and comprises a mutation to Gln; wherein the amino acid is at position Leu571 and comprises a mutation to Phe or Ile or Met or Trp; wherein the amino acid is at position Glu576 and comprises a mutation to Leu; wherein the amino acid is at position Glu580 and comprises a mutation to Ile or Lys or Gln or Arg or Val or Met; wherein the amino acid is at position Thr590 and comprises a mutation to Lys; wherein the amino acid is at position Ala595 and comprises a mutation to Met; or wherein the amino acid is at position Ile603 and comprises a mutation to Asp, or a combination thereof. ;
[0210] Aspect 2 is an altered archaeal B family DNA polymerase according to aspect 1, wherein the amino acid is at position Leu333 and comprises a mutation to His; wherein the amino acid is at position Ser347 and comprises a mutation to Asp or Arg; wherein the amino acid is at position Asn399 and comprises a mutation to Met; wherein the amino acid is at position Phe405 and comprises a mutation to Met; wherein the amino acid is at position Tyr481 and comprises a mutation to Ile; wherein the amino acid is at position Val485 and comprises a mutation to Asn; wherein the amino acid is at position Ile486 and comprises a mutation to Lys; wherein the amino acid is at position Trp504 and comprises a mutation to Asn; wherein the amino acid is at position Glu511 and comprises a mutation to Lys or Met; wherein the amino acid is at position Asn568 and comprises a mutation to Gln; or wherein the amino acid is at position Glu580 and comprises a mutation to Ile or Lys or Gln or Arg or Val, or a combination thereof.
[0211] Aspect 3 is an altered archaeal B family DNA polymerase according to aspect 1 or 2, wherein the amino acid is at position Asn269 and comprises a mutation to Gly or Val; wherein the amino acid is at position Leu333 and comprises a mutation to Ile; wherein the amino acid is at position Ser347 and comprises a mutation to Glu or Val; wherein the amino acid is at position Asn399 and comprises a mutation to Ala; wherein the amino acid is at position Phe405 and comprises a mutation to Lys or Gln; wherein the amino acid is at position Ile412 and comprises a mutation to Val; wherein the amino acid is at position Glu459 and comprises a mutation to Thr. wherein the amino acid is at position Gln461 and comprises a mutation to Trp; wherein the amino acid is at position Val485 and comprises a mutation to Gly or Met or Gln or Ser or Thr; wherein the amino acid is at position Glu511 and comprises a mutation to Arg; wherein the amino acid is at position Trp516 and comprises a mutation to Ile or Lys or Met or Gln; wherein the amino acid is at position Tyr520 and comprises a mutation to Ala; wherein the amino acid is at position Ile567 and comprises a mutation to Leu; or wherein the amino acid is at position Glu580 and comprises a mutation to Met, or a combination thereof.
[0212] Aspect 4 is an altered archaeal B family DNA polymerase, comprising an amino acid substitution mutation at a position functionally equivalent to Glu580 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1.
[0213] Aspect 5 is the altered archaeal B family DNA polymerase according to aspect 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to a polar amino acid.
[0214] Aspect 6 is the altered archaeal family B DNA polymerase according to aspect 4 or 5, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys or Arg.
[0215] Aspect 7 is an altered archaeal B-family DNA polymerase according to any one of aspects 4 to 6, which further comprises an amino acid substitution mutation at a position functionally equivalent to Phe405 in the reference archaeal B-family DNA polymerase.
[0216] Aspect 8 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 7, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
[0217] Aspect 9 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 8, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
[0218] Aspect 10 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 9, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Arg, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Phe405 including a mutation to Met.
[0219] Aspect 11 is an altered archaeal B-family DNA polymerase according to any one of aspects 4 to 10, which further comprises an amino acid substitution mutation at a position functionally equivalent to Val485 in the reference archaeal B-family DNA polymerase.
[0220] Aspect 12 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 11, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to a polar or uncharged amino acid.
[0221] Aspect 13 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 12, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Thr.
[0222] Aspect 14 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 13, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Val485 including a mutation to Thr.
[0223] Aspect 15 is an altered archaeal B-family DNA polymerase according to any one of aspects 4 to 14, which further comprises an amino acid substitution mutation at a position functionally equivalent to Trp516 in the reference archaeal B-family DNA polymerase.
[0224] Aspect 16 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 15, wherein the substitution mutation at the position functionally equivalent to Trp516 comprises a mutation to a non-polar or hydrophobic amino acid.
[0225] Aspect 17 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 16, wherein the substitution mutation at the position functionally equivalent to Trp516 comprises a mutation to Met or a mutation to Leu.
[0226] Aspect 18 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 17, which further comprises an amino acid substitution mutation at a position functionally equivalent to Leu571 in the reference archaeal Family B DNA polymerase.
[0227] Aspect 19 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 18, wherein the substitution mutation at the position functionally equivalent to Leu571 comprises a mutation to a non-polar or hydrophobic amino acid.
[0228] Aspect 20 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 19, wherein the substitution mutation at the position functionally equivalent to Leu571 comprises a mutation to Phe or Met.
[0229] Aspect 21 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 20, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also contains a substitution mutation at the position functionally equivalent to Leu571 including a mutation to Phe, or wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Gln, and the altered archaeal B family DNA polymerase also contains a substitution mutation at the position functionally equivalent to Leu571 including a mutation to Met.
[0230] Aspect 22 is an altered archaeal B family DNA polymerase according to any one of aspects 4 to 21, which further comprises an amino acid substitution mutation at a position functionally equivalent to Ala408, Ile410, or both Ala408 and Ile410 in the reference archaeal B family DNA polymerase.
[0231] Aspect 23 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 22, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
[0232] Aspect 24 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 4 to 23, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
[0233] Aspect 25 is an altered archaeal Family B DNA polymerase according to any one of Aspects 4 to 24, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
[0234] Aspect 26 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 25, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0235] Aspect 27 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 26, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also comprises a substitution mutation at a position functionally equivalent to Trp516 including a mutation to Met or a mutation to Leu.
[0236] Aspect 28 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 27, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Ala408 including a mutation to Ser and a substitution mutation at a position functionally equivalent to Ile410 including a mutation to Val.
[0237] Aspect 29 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 28, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Ala408 including a mutation to Ser.
[0238] Aspect 30 is an altered archaeal B family DNA polymerase according to any one of aspects 4 to 29, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also comprises a substitution mutation at the position functionally equivalent to Phe405 including a mutation to a non-polar or hydrophobic amino acid.
[0239] Aspect 31 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 4 to 30, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
[0240] Aspect 32 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 31, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Phe405 including a mutation to Met.
[0241] Aspect 33 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 32, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at the position functionally equivalent to Ile410 including a mutation to a non-polar amino acid.
[0242] Aspect 34 is an altered archaeal Family B DNA polymerase according to any one of aspects 4 to 33, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0243] Aspect 35 is an altered archaeal B family DNA polymerase according to any one of Aspects 4 to 34, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase also includes a substitution mutation at a position functionally equivalent to Ile410 including a mutation to Val.
[0244] Aspect 36 is an altered archaeal B family DNA polymerase, comprising amino acid substitution mutations at positions functionally equivalent to Phe405 and Val485 in a reference archaeal B family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1.
[0245] Aspect 37 is an altered archaeal Family B DNA polymerase according to aspect 36, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
[0246] Aspect 38 is an altered archaeal Family B DNA polymerase according to aspect 36 or 37, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
[0247] Aspect 39 is an altered archaeal Family B DNA polymerase according to any one of aspects 36 to 38, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to a non-polar or hydrophobic or uncharged amino acid.
[0248] Aspect 40 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 36 to 39, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly.
[0249] Aspect 41 is an altered archaeal B family DNA polymerase according to any one of aspects 36 to 40, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly.
[0250] Aspect 42 is an altered archaeal B family DNA polymerase according to any one of aspects 36 to 41, which further comprises an amino acid substitution mutation at a position functionally equivalent to Ala408, Ile410, or both Ala408 and Ile410 in the reference archaeal B family DNA polymerase.
[0251] Aspect 43 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 36 to 42, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
[0252] Aspect 44 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 36 to 43, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
[0253] Aspect 45 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 36 to 44, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
[0254] Aspect 46 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 36 to 45, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0255] Aspect 47 is an altered archaeal B family DNA polymerase according to any one of Aspects 36 to 46, wherein the substitution mutation at the position functionally equivalent to Phe405 includes a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 includes a mutation to Gly, and the altered archaeal B family DNA polymerase also comprises a substitution mutation at a position functionally equivalent to Ala408 including a mutation to Ser and a substitution mutation at a position functionally equivalent to Ile410 including a mutation to Val.
[0256] Aspect 48 is an altered archaeal B family DNA polymerase according to any one of Aspects 36 to 47, wherein the substitution mutation at the position functionally equivalent to Phe405 includes a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 includes a mutation to Gly, and the altered archaeal B family DNA polymerase also comprises a substitution mutation at the position functionally equivalent to Ala408 including a mutation to Ser.
[0257] Aspect 49 is an altered archaeal B family DNA polymerase, comprising amino acid substitution mutations at positions Phe405 and Ile410 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO: 1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1.
[0258] Aspect 50 is an altered archaeal Family B DNA polymerase according to aspect 49, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
[0259] Aspect 51 is an altered archaeal Family B DNA polymerase according to aspect 49 or 50, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
[0260] Aspect 52 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 51, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar amino acid.
[0261] Aspect 53 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 52, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0262] Aspect 54 is an altered archaeal B family DNA polymerase according to any one of Aspects 49 to 53, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0263] Aspect 55 is an altered archaeal B family DNA polymerase, comprising amino acid substitution mutations at positions Phe140 and Ser407 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO: 1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO: 1.
[0264] Aspect 56 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 55, wherein the substitution mutation at the position functionally equivalent to Phe140 comprises a mutation to a non-polar or hydrophobic amino acid.
[0265] Aspect 57 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 56, wherein the substitution mutation at the position functionally equivalent to Phe140 comprises a mutation to Leu.
[0266] Aspect 58 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 57, wherein the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to a non-polar or hydrophobic amino acid.
[0267] Aspect 59 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 49 to 58, wherein the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to Leu.
[0268] Aspect 60 is an altered archaeal Family B DNA polymerase according to any one of Aspects 49 to 59, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu, and the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to Leu.
[0269] Aspect 61 is an altered archaeal B family DNA polymerase, which comprises amino acid substitution mutations at positions Leu403, Ala408, Ile410 and Gly497 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO:1, and compared to SEQ ID NO:1, the altered archaeal B family DNA polymerase is capable of incorporating modified nucleotides comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii).
[0270] Aspect 62 is an altered archaeal Family B DNA polymerase according to aspect 61, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to a non-polar or hydrophobic amino acid.
[0271] Aspect 63 is an altered archaeal Family B DNA polymerase according to aspect 61 or 62, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to Met.
[0272] Aspect 64 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 63, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
[0273] Aspect 65 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 64, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
[0274] Aspect 66 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 65, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
[0275] Aspect 67 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 66, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0276] Aspect 68 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 67, wherein the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to a non-polar or hydrophobic amino acid.
[0277] Aspect 69 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 61 to 68, wherein the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to Met.
[0278] Aspect 70 is an altered archaeal B family DNA polymerase according to any one of Aspects 61 to 69, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to Met, the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val, and the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to Met.
[0279] Aspect 71 is an altered archaeal B family DNA polymerase, which comprises amino acid substitution mutations at positions Phe405, Ile410, Ile412, Thr514 and Ile521 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO:1, and compared to SEQ ID NO:1, the altered archaeal B family DNA polymerase is capable of incorporating modified nucleotides comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii).
[0280] Aspect 72 is an altered archaeal Family B DNA polymerase according to aspect 71, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
[0281] Aspect 73 is an altered archaeal Family B DNA polymerase according to aspect 71 or 72, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Ile.
[0282] Aspect 74 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 73, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
[0283] Aspect 75 is an altered Archaebacterial Family B DNA polymerase according to any one of Aspects 71 to 74, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Pro.
[0284] Aspect 76 is an altered Archaebacterial Family B DNA polymerase according to any one of Aspects 71 to 75, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to a non-polar or hydrophobic amino acid.
[0285] Aspect 77 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 76, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Met.
[0286] Aspect 78 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 77, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to a non-polar or hydrophobic amino acid.
[0287] Aspect 79 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 78, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala.
[0288] Aspect 80 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 79, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to a non-polar or hydrophobic amino acid.
[0289] Aspect 81 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 71 to 80, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
[0290] Aspect 82 is an altered archaeal B family DNA polymerase according to any one of Aspects 71 to 81, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Ile, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Pro, the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Met, the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala, and the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
[0291] Aspect 83 is an altered archaeal B family DNA polymerase, which comprises amino acid substitution mutations at positions Phe405, Ala408, Ile410, Ile412, Thr514, and Ile521 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO: 1, and compared to SEQ ID NO: 1, the altered archaeal B family DNA polymerase is capable of incorporating modified nucleotides comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii).
[0292] Aspect 84 is an altered Archaebacterial Family B DNA polymerase according to aspect 83, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
[0293] Aspect 85 is an altered Archaebacterial Family B DNA polymerase according to aspect 83 or 84, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu.
[0294] Aspect 86 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 85, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
[0295] Aspect 87 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 86, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
[0296] Aspect 88 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 87, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
[0297] Aspect 89 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 88, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
[0298] Aspect 90 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 89, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to a polar or uncharged amino acid.
[0299] Aspect 91 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 90, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Thr.
[0300] Aspect 92 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 91, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to a non-polar or hydrophobic amino acid.
[0301] Aspect 93 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 92, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala.
[0302] Aspect 94 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 93, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to a non-polar or hydrophobic amino acid.
[0303] Aspect 95 is an altered Archaebacterial Family B DNA polymerase according to any one of aspects 83 to 94, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
[0304] Aspect 96 is an altered archaeal B family DNA polymerase according to any one of aspects 83 to 95, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu, the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val, the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Thr, the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala, and the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
[0305] Aspect 97 is an altered archaeal B family DNA polymerase, the altered archaeal B family DNA polymerase comprising the amino acid sequence of any one of SEQ ID NO:2 to SEQ ID NO:8 or any one of SEQ ID NO:16 to SEQ ID NO:32.
[0306] Aspect 98 is an altered Archaeal Family B DNA polymerase according to any one of aspects 1 to 97, wherein the polymerase comprises reduced exonuclease activity compared to SEQ ID NO:9.
[0307] Aspect 99 is a nucleic acid molecule encoding a DNA polymerase as defined in any one of aspects 1 to 98.
[0308] Aspect 100 is an expression vector comprising the nucleic acid molecule according to aspect 99.
[0309] Aspect 101 is a host cell comprising the vector according to aspect 100.
[0310] Aspect 102 is a method for incorporating a modified nucleotide into a polynucleotide complementary to a target nucleotide, the method comprising allowing the following components to interact: (i) an altered archaeal B family DNA polymerase according to one of aspects 1 to 97, (ii) a DNA template; and (iii) a nucleotide solution.
[0311] Aspect 103 is a method according to aspect 102, wherein the DNA template comprises a clustered array.
[0312] Aspect 104 is a kit for performing a nucleotide incorporation reaction, the kit comprising: the altered archaeal Family B DNA polymerase according to any one of aspects 1 to 97, and a solution comprising a second-generation fully functional nucleotide.
[0313] Aspect 105 is a kit according to aspect 104, wherein the second generation fully functional nucleotide comprises a detectable label.
[0314] Aspect 106 is a kit according to aspect 104 or 105, wherein the second generation fully functional nucleotide has been modified at the 3' sugar hydroxyl group such that the substituent is larger in size than the naturally occurring 3' hydroxyl group.
[0315] Aspect 107 is a kit according to any one of aspects 104 to 106, wherein the second-generation fully functional nucleotide comprises a modified nucleotide molecule, the modified nucleotide molecule comprises a purine or pyrimidine base and a deoxyribose portion, and the deoxyribose portion comprises a removable 3'-OH acetal capping group or a 3'-OH thiocarbamate capping group attached to the 3' carbon of the deoxyribose portion.
[0316] Aspect 108 is a kit according to any one of aspects 104 to 107, wherein the 3'-OH acetal capping group has the structure
[0317]
[0318] wherein the *** represents the point of attachment of the 3'-OH acetal capping group to the 3' carbon of the modified nucleotide sugar.
[0319] Aspect 109 is a kit according to any one of aspects 104 to 108, wherein the second generation fully functional nucleotide comprises a nucleotide molecule comprising a purine or pyrimidine base linked to a detectable label via a cleavable linker.
[0320] Aspect 110 is a kit according to any one of aspects 104 to 109, wherein the detectable label comprises a fluorescent label.
[0321] Aspect 111 is a kit according to any one of aspects 104 to 110, wherein the cleavable linker is selected from the group consisting of:
[0322]
[0323] wherein Z is —O—CH 2 —CH═CH 2 ; n is an integer of 1, 2, 3, 4 or 5; * represents the connection point between the cleavable linker and the purine or pyrimidine base; and ** represents the connection point between the cleavable linker and the detectable label.
[0324] Aspect 112 is a kit according to any one of aspects 104 to 111, further comprising one or more DNA template molecules and / or primers.
[0325] Example
[0326] The present disclosure is illustrated by the following examples.It is to be understood that the specific examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the present disclosure as described herein.
[0327] Error rates and phasing values were compared using sequencing experiments. Unless otherwise stated, experiments were performed on MiniSeq TMSystem (Illumina, Inc., San Diego, Calif.) is carried out, for example, for each polymerase, a separate incorporation mixture (IMX) is prepared and used in a short read of 30 seconds or 20 seconds allowing reaction time. In the case of short reads, the use of a modified test kit allows 6 to 9 different incorporation mixtures. The modification of the test kit includes replacing the deblocking reagent and the deblocking scavenger washing buffer. In these experiments, the first reading and the second reading include internal controls for analyzing phasing values and error rates to evaluate polymerase performance. The first reading and the second reading are used to establish the baseline performance of the control polymerase and the custom IMX formulation. The last reading is used to evaluate the potential quality decline during the entire run. When the polymerase with a single substitution mutation is compared in the sequencing run, SEQ ID NO: 1 is used as a control, and when the polymerase with two or more substitution mutations is compared in the sequencing run, SEQ ID NO: 2 is used as a control.
[0328] Primary screening
[0329] Error rates and phasing values were compared using sequencing experiments. Unless otherwise stated, experiments were performed on MiniSeq TM System (Illumina, Inc., San Diego, Calif.), for example, for each polymerase, a separate incorporation mixture (IMX) is prepared and used in a short read allowing a reaction time of 30 seconds. Using a modified MiniSeq medium-throughput output cartridge formulation, the standard polymerase is replaced with a polymerase to be tested. The use of a modified test kit allows 6 to 9 different incorporation mixtures. In these experiments, the first reading and the second reading include internal controls for analyzing phasing values and error rates to evaluate polymerase performance. The first reading is used to establish a baseline performance of a control polymerase and a custom IMX formulation. The last reading is used to evaluate the potential quality reduction during the entire run. For every 36 cycles containing different polymerases, the observed phasing values and error rates are reported. By dividing the observed phasing rate and error rate by the phasing rate and error rate of the Read 1 control, the phasing value and error rate value of the mutant are normalized relative to the Read 1 control. Mutants with normalized phasing values equal to or less than 1.2 were selected for secondary screening (Figure 2).
[0330] Secondary screening
[0331] Error rates and phasing values were compared using sequencing experiments. Unless otherwise stated, experiments were performed on the MiniSeq TMSystem (Illumina, Inc., San Diego, Calif.), for example, for each polymerase, a separate incorporation mixture (IMX) is prepared and used in a short read of 30 seconds of allowed reaction time. Using a modified MiniSeq medium-throughput output cartridge formulation, the standard polymerase is replaced with a polymerase to be tested. The use of a modified test kit allows 6 to 9 different incorporation mixtures. In these experiments, the first reading, the second reading, and the last reading include internal controls for analyzing phasing values and error rates to evaluate polymerase performance. The first reading is used to establish the baseline performance of the control polymerase and the custom IMX formulation under permissive conditions, allowing a reaction time of 30 seconds. The second reading is used to determine the performance of the control polymerase and the custom IMX formulation under stress conditions, allowing a reaction time of 20 seconds. The last reading is used to evaluate the potential quality degradation of stress conditions during the entire run, allowing a reaction time of 20 seconds. For every 36 cycles containing different polymerases, the observed phasing values and error rates are reported. The phasing values and error rate values of the mutants were normalized relative to the Read 2 control. Normalized values were obtained by dividing the observed phasing rate and error rate by the phasing rate and error rate of the Read 2 control. Mutants with an average normalized value of less than or equal to 0.5 were classified as level 1 ( Figure 3 ). Mutants with an average normalized value greater than 0.5 and less than or equal to 1.0 were classified as level 2 (Figure 4). Mutants with an average normalized phasing value greater than 1.0 were not classified.
[0332] Tier 1 and 2 mutations were recombined to further identify any additional improvements to sequencing performance - some exemplary double mutants are in Figure 5 Shown in.
[0333] Finally, in some cases, these double mutants or similar recombinations can be used as new backbones to which additional mutations are added before validation in a 150 cycle run ( Figure 6 ) – Example of a 151 cycle validation run.
[0334] Verification run (150 cycles)
[0335] In some cases, polymerases are prepared for long runs ( Figure 7 ). A modified MiniSeq medium throughput output cartridge formulation was used, with the polymerase to be tested replacing the standard polymerase. The incubation time of IMX on the flow cell was varied as described in the Examples herein. Phasing values and error rates were recorded and compared to control values observed under the same conditions.
[0336] The complete disclosures of all patents, patent applications, and publications cited herein, as well as electronically available materials (including, for example, nucleotide sequence submissions in, for example, GenBank and RefSeq, amino acid sequence submissions in, for example, SwissProt, PIR, PRF, PDB, and translations of annotated coding regions from GenBank and RefSeq) are incorporated by reference in their entirety. Supplementary materials cited in publications (such as supplementary tables, supplementary figures, supplementary materials and methods, and / or supplementary experimental data) are also incorporated by reference in their entirety. In the event of any inconsistency between the disclosure of the present application and the disclosure of any document incorporated herein by reference, the disclosure of the present application shall prevail. The above detailed description and examples are given only for a clear understanding of the present invention. They should not be construed as unnecessary limitations. The present disclosure is not limited to the exact details shown and described, as variations obvious to those skilled in the art will be included in the disclosure defined by the claims.
[0337] Unless otherwise indicated, all numbers indicating the amount of a component, molecular weight, etc., used in the specification and claims are to be understood in all cases as modified by the term "about". Therefore, unless otherwise indicated, the numerical parameters listed in the specification and claims are approximate values that may vary depending on the desired properties sought to be obtained by the present disclosure. At the very least, and not attempting to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be interpreted in light of the number of reported significant digits and by applying customary rounding techniques.
[0338] Although the numerical ranges and parameters setting forth the broad scope of the present disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. However, all numerical values inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements.
[0339] Unless otherwise indicated, all headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading.
Claims
1. An altered archaeal B-family DNA polymerase, wherein the altered archaeal B-family DNA polymerase comprises an amino acid substitution mutation at a position that is functionally equivalent to an amino acid in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1. wherein the amino acid is at position Arg58 and comprises a mutation to Leu; wherein the amino acid is at position Tyr261 and comprises a mutation to Gly; wherein the amino acid is at position Asn269 and comprises a mutation to Gly or Val; wherein the amino acid is at position Phe283 and comprises a mutation to Ile or Lys; wherein the amino acid is at position Pro328 and comprises a mutation to Asp; wherein the amino acid is at position Met329 and comprises a mutation to Thr; wherein the amino acid is at position Gln332 and comprises a mutation to Ser; wherein the amino acid is at position Leu333 and comprises a mutation to His or Ile; wherein the amino acid is at position Ser347 and comprises a mutation to Asp or Arg or Glu or Val or Thr; wherein the amino acid is at position Asn399 and comprises a mutation to Met or Ala; wherein the amino acid is at position Phe405 and comprises a mutation to Met or Lys or Gln; wherein the amino acid is at position Arg406 and comprises a mutation to Met; wherein the amino acid is at position Ile410 and comprises a mutation to Val; wherein the amino acid is at position Ile412 and comprises a mutation to Val; wherein the amino acid is at position Glu458 and comprises a mutation to Gly; wherein the amino acid is at position Glu459 and comprises a mutation to Thr or Asp; wherein the amino acid is at position Gln461 and comprises a mutation to Trp; wherein the amino acid is at position Ala469 and comprises a mutation to Glu; wherein the amino acid is at position Tyr481 and comprises a mutation to Ile; wherein the amino acid is at position Val485 and comprises a mutation to Asn or Gly or Met or Gln or Ser or Thr; wherein the amino acid is at position Ile486 and comprises a mutation to Leu; wherein the amino acid is at position Trp504 and comprises a mutation to Asn; wherein the amino acid is at position Lys507 and comprises a mutation to His or Pro; wherein the amino acid is at position Glu511 and comprises a mutation to Lys or Met or Arg; wherein the amino acid is at position Trp516 and comprises a mutation to Ile or Lys or Met or Gln or Leu; wherein the amino acid is at position Tyr520 and comprises a mutation to Ala; wherein the amino acid is at position Ile521 and comprises a mutation to Thr; wherein the amino acid is at position Met523 and comprises a mutation to Ile or Thr; wherein the amino acid is at position Arg526 and comprises a mutation to Asn; wherein the amino acid is at position Glu527 and comprises a mutation to Ile; wherein the amino acid is at position Leu528 and comprises a mutation to Thr; wherein the amino acid is at position Ile567 and comprises a mutation to Leu; wherein the amino acid is at position Asn568 and comprises a mutation to Gln; wherein the amino acid is at position Leu571 and comprises a mutation to Phe or Ile or Met or Trp; wherein the amino acid is at position Glu576 and comprises a mutation to Leu; wherein the amino acid is at position Glu580 and comprises a mutation to Ile or Lys or Gln or Arg or Val or Met; wherein the amino acid is at position Thr590 and comprises a mutation to Lys; wherein the amino acid is at position Ala595 and comprises a mutation to Met; or Wherein the amino acid is at position Ile603 and comprises a mutation to Asp.
2. The altered archaeal family B DNA polymerase according to claim 1, wherein the amino acid is at position Leu333 and comprises a mutation to His; wherein the amino acid is at position Ser347 and comprises a mutation to Asp or Arg; wherein the amino acid is at position Asn399 and comprises a mutation to Met; wherein the amino acid is at position Phe405 and comprises a mutation to Met; wherein the amino acid is at position Tyr481 and comprises a mutation to Ile; wherein the amino acid is at position Val485 and comprises a mutation to Asn; wherein the amino acid is at position Ile486 and comprises a mutation to Lys; wherein the amino acid is at position Trp504 and comprises a mutation to Asn; wherein the amino acid is at position Glu511 and comprises a mutation to Lys or Met; wherein the amino acid is at position Asn568 and comprises a mutation to Gln; or Wherein the amino acid is at position Glu580 and comprises a mutation to Ile or Lys or Gln or Arg or Val.
3. The altered archaeal family B DNA polymerase according to claim 1, wherein the amino acid is at position Asn269 and comprises a mutation to Gly or Val; wherein the amino acid is at position Leu333 and comprises a mutation to Ile; wherein the amino acid is at position Ser347 and comprises a mutation to Glu or Val; wherein the amino acid is at position Asn399 and comprises a mutation to Ala; wherein the amino acid is at position Phe405 and comprises a mutation to Lys or Gln; wherein the amino acid is at position Ile412 and comprises a mutation to Val; wherein the amino acid is at position Glu459 and comprises a mutation to Thr; wherein the amino acid is at position Gln461 and comprises a mutation to Trp; wherein the amino acid is at position Val485 and comprises a mutation to Gly or Met or Gln or Ser or Thr; wherein the amino acid is at position Glu511 and comprises a mutation to Arg; wherein the amino acid is at position Trp516 and comprises a mutation to Ile or Lys or Met or Gln; wherein the amino acid is at position Tyr520 and comprises a mutation to Ala; wherein the amino acid is at position Ile567 and comprises a mutation to Leu; or Wherein the amino acid is at position Glu580 and comprises a mutation to Met.
4. An altered archaeal B-family DNA polymerase, comprising an amino acid substitution mutation at a position functionally equivalent to Glu580 in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
5. The altered archaeal Family B DNA polymerase according to claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to a polar amino acid.
6. The altered archaeal Family B DNA polymerase according to claim 5, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys or Arg.
7. The altered archaeal B-family DNA polymerase of claim 4, further comprising an amino acid substitution mutation at a position functionally equivalent to Phe405 in the reference archaeal B-family DNA polymerase.
8. The altered archaeal Family B DNA polymerase of claim 7, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
9. The altered archaeal Family B DNA polymerase of claim 8, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
10. The altered archaeal B family DNA polymerase according to claim 8, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Arg, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Phe405 comprising a mutation to Met.
11. The altered archaeal B-family DNA polymerase of claim 4, further comprising an amino acid substitution mutation at a position functionally equivalent to Val485 in the reference archaeal B-family DNA polymerase.
12. The altered archaeal Family B DNA polymerase of claim 11, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to a polar or uncharged amino acid.
13. The altered archaeal Family B DNA polymerase of claim 12, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Thr.
14. The altered archaeal B family DNA polymerase according to claim 12, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Val485 comprising a mutation to Thr.
15. The altered archaeal B-family DNA polymerase of claim 4, further comprising an amino acid substitution mutation at a position functionally equivalent to Trp516 in the reference archaeal B-family DNA polymerase.
16. The altered archaeal Family B DNA polymerase of claim 15, wherein the substitution mutation at the position functionally equivalent to Trp516 comprises a mutation to a non-polar or hydrophobic amino acid.
17. The altered archaeal Family B DNA polymerase according to claim 16, wherein the substitution mutation at the position functionally equivalent to Trp516 comprises a mutation to Met or a mutation to Leu.
18. The altered archaeal B-family DNA polymerase of claim 4, further comprising an amino acid substitution mutation at a position functionally equivalent to Leu571 in the reference archaeal B-family DNA polymerase.
19. The altered archaeal Family B DNA polymerase of claim 18, wherein the substitution mutation at the position functionally equivalent to Leu571 comprises a mutation to a non-polar or hydrophobic amino acid.
20. The altered archaeal Family B DNA polymerase of claim 19, wherein the substitution mutation at the position functionally equivalent to Leu571 comprises a mutation to Phe or Met.
21. The altered archaeal B family DNA polymerase according to claim 19, wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at the position functionally equivalent to Leu571 including a mutation to Phe, or wherein the substitution mutation at the position functionally equivalent to Glu580 includes a mutation to Gln, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at the position functionally equivalent to Leu571 including a mutation to Met.
22. The altered archaeal B-family DNA polymerase of claim 4, further comprising an amino acid substitution mutation at a position functionally equivalent to Ala408, Ile410, or both Ala408 and Ile410 in the reference archaeal B-family DNA polymerase.
23. The altered archaeal Family B DNA polymerase of claim 22, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
24. The altered Archaebacterial Family B DNA polymerase of claim 23, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
25. The altered archaeal Family B DNA polymerase of claim 22, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
26. The altered archaeal Family B DNA polymerase of claim 25, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
27. The altered archaeal B family DNA polymerase according to claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Trp516 comprising a mutation to Met or a mutation to Leu.
28. The altered archaeal B family DNA polymerase according to claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Ala408 comprising a mutation to Ser and a substitution mutation at a position functionally equivalent to Ile410 comprising a mutation to Val.
29. The altered archaeal B-family DNA polymerase of claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B-family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Ala408 comprising a mutation to Ser.
30. The altered archaeal B-family DNA polymerase according to claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B-family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Phe405 comprising a mutation to a non-polar or hydrophobic amino acid.
31. The altered Archaebacterial Family B DNA polymerase of claim 30, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
32. The altered archaeal B-family DNA polymerase according to claim 31, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B-family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Phe405 comprising a mutation to Met.
33. The altered archaeal B family DNA polymerase according to claim 4, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at the position functionally equivalent to Ile410 comprising a mutation to a non-polar amino acid.
34. The altered archaeal Family B DNA polymerase of claim 33, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
35. The altered archaeal B family DNA polymerase according to claim 34, wherein the substitution mutation at the position functionally equivalent to Glu580 comprises a mutation to Lys, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Ile410 comprising a mutation to Val.
36. An altered archaeal B-family DNA polymerase, comprising amino acid substitution mutations at positions functionally equivalent to Phe405 and Val485 in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
37. The altered Archaebacterial Family B DNA polymerase of claim 36, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
38. The altered Archaebacterial Family B DNA polymerase of claim 37, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
39. The altered archaeal Family B DNA polymerase of claim 36, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to a non-polar or hydrophobic or uncharged amino acid.
40. The altered Archaebacterial Family B DNA polymerase of claim 37, wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly.
41. The altered archaeal Family B DNA polymerase of claim 36, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly.
42. The altered archaeal B-family DNA polymerase of claim 36, further comprising an amino acid substitution mutation at a position functionally equivalent to Ala408, Ile410, or both Ala408 and Ile410 in the reference archaeal B-family DNA polymerase.
43. The altered Archaebacterial Family B DNA polymerase of claim 42, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
44. The altered Archaebacterial Family B DNA polymerase of claim 43, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
45. The altered archaeal Family B DNA polymerase of claim 42, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
46. The altered Archaebacterial Family B DNA polymerase of claim 45, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
47. The altered archaeal B family DNA polymerase according to claim 36, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Ala408 comprising a mutation to Ser and a substitution mutation at a position functionally equivalent to Ile410 comprising a mutation to Val.
48. The altered archaeal B family DNA polymerase according to claim 36, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to Gly, and the altered archaeal B family DNA polymerase further comprises a substitution mutation at a position functionally equivalent to Ala408 comprising a mutation to Ser.
49. An altered archaeal B-family DNA polymerase, comprising amino acid substitution mutations at positions functionally equivalent to Phe405 and Ile410 in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
50. The altered Archaebacterial Family B DNA polymerase of claim 49, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
51. The altered Archaebacterial Family B DNA polymerase of claim 50, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met.
52. The altered Archaebacterial Family B DNA polymerase of claim 49, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar amino acid.
53. The altered Archaebacterial Family B DNA polymerase of claim 52, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
54. The altered archaeal Family B DNA polymerase of claim 49, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Met, and the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
55. An altered archaeal B-family DNA polymerase, comprising amino acid substitution mutations at positions functionally equivalent to Phe140 and Ser407 in a reference archaeal B-family DNA polymerase of SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
56. The altered Archaebacterial Family B DNA polymerase of claim 55, wherein the substitution mutation at the position functionally equivalent to Phe140 comprises a mutation to a non-polar or hydrophobic amino acid.
57. The altered Archaebacterial Family B DNA polymerase of claim 56, wherein the substitution mutation at the position functionally equivalent to Phe140 comprises a mutation to Leu.
58. The altered Archaebacterial Family B DNA polymerase of claim 55, wherein the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to a non-polar or hydrophobic amino acid.
59. The altered Archaebacterial Family B DNA polymerase of claim 58, wherein the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to Leu.
60. The altered Archaebacterial Family B DNA polymerase of claim 55, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu, and the substitution mutation at the position functionally equivalent to Ser407 comprises a mutation to Leu.
61. An altered archaeal B family DNA polymerase, comprising amino acid substitution mutations at positions Leu403, Ala408, Ile410 and Gly497 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO:1, and the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
62. The altered Archaebacterial Family B DNA polymerase of claim 61, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to a non-polar or hydrophobic amino acid.
63. The altered Archaebacterial Family B DNA polymerase of claim 62, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to Met.
64. The altered Archaebacterial Family B DNA polymerase of claim 61, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
65. The altered Archaebacterial Family B DNA polymerase of claim 64, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
66. The altered Archaebacterial Family B DNA polymerase of claim 61, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
67. The altered Archaebacterial Family B DNA polymerase of claim 66, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
68. The altered Archaebacterial Family B DNA polymerase of claim 61, wherein the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to a non-polar or hydrophobic amino acid.
69. The altered Archaebacterial Family B DNA polymerase of claim 68, wherein the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to Met.
70. The altered archaeal B family DNA polymerase of claim 61, wherein the substitution mutation at the position functionally equivalent to Leu403 comprises a mutation to Met, the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val, and the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to Met.
71. An altered archaeal B family DNA polymerase, comprising amino acid substitution mutations at positions Phe405, Ile410, Ile412, Thr514 and Ile521 in a reference archaeal B family DNA polymerase functionally equivalent to SEQ ID NO: 1, and compared to SEQ ID NO: 1, the altered archaeal B family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group with (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii).
72. The altered Archaebacterial Family B DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
73. The altered Archaebacterial Family B DNA polymerase of claim 72, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Ile.
74. The altered Archaebacterial Family B DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
75. The altered Archaebacterial Family B DNA polymerase of claim 74, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Pro.
76. The altered Archaebacterial Family B DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to a non-polar or hydrophobic amino acid.
77. The altered Archaebacterial Family B DNA polymerase of claim 76, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Met.
78. The altered Archaebacterial Family B DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to a non-polar or hydrophobic amino acid.
79. The altered Archaebacterial Family B DNA polymerase of claim 78, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala.
80. The altered Archaebacterial Family B DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to a non-polar or hydrophobic amino acid.
81. The altered Archaebacterial Family B DNA polymerase of claim 80, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
82. The altered archaeal B family DNA polymerase of claim 71, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Ile, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Pro, the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Met, the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala, and the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
83. An altered archaeal B-family DNA polymerase, comprising amino acid substitution mutations at positions Phe405, Ala408, Ile410, Ile412, Thr514, Ile521 in a reference archaeal B-family DNA polymerase functionally equivalent to SEQ ID NO: 1, and the altered archaeal B-family DNA polymerase is capable of incorporating a modified nucleotide comprising a 3'-OH acetal blocking group or a 3'-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii) compared to SEQ ID NO:
1.
84. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to a non-polar or hydrophobic amino acid.
85. The altered Archaebacterial Family B DNA polymerase of claim 84, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu.
86. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid.
87. The altered Archaebacterial Family B DNA polymerase of claim 86, wherein the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser.
88. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to a non-polar or hydrophobic amino acid.
89. The altered Archaebacterial Family B DNA polymerase of claim 88, wherein the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val.
90. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to a polar or uncharged amino acid.
91. The altered Archaebacterial Family B DNA polymerase of claim 90, wherein the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Thr.
92. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to a non-polar or hydrophobic amino acid.
93. The altered Archaebacterial Family B DNA polymerase of claim 92, wherein the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala.
94. The altered Archaebacterial Family B DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to a non-polar or hydrophobic amino acid.
95. The altered Archaebacterial Family B DNA polymerase of claim 94, wherein the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
96. The altered archaeal B family DNA polymerase of claim 83, wherein the substitution mutation at the position functionally equivalent to Phe405 comprises a mutation to Leu, the substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Ser, the substitution mutation at the position functionally equivalent to Ile410 comprises a mutation to Val, the substitution mutation at the position functionally equivalent to Ile412 comprises a mutation to Thr, the substitution mutation at the position functionally equivalent to Thr514 comprises a mutation to Ala, and the substitution mutation at the position functionally equivalent to Ile521 comprises a mutation to Ala.
97. An altered archaeal B-family DNA polymerase, comprising the amino acid sequence of any one of SEQ ID NO:2 to SEQ ID NO:8 or any one of SEQ ID NO:16 to SEQ ID NO:
32.
98. The altered Archaebacterial Family B DNA polymerase of claims 1, 4, 36, 49, 55, 61, 71, 83 or 97, wherein the polymerase comprises reduced exonuclease activity compared to SEQ ID NO:
9.
99. A nucleic acid molecule encoding a DNA polymerase as defined in any one of claims 1 to 98.
100. An expression vector comprising the nucleic acid molecule according to claim 99.
101. A host cell comprising the vector according to claim 100.
102. A method for incorporating modified nucleotides into a polynucleotide that is complementary to a target nucleotide, the method comprising allowing the following components to interact: (i) an altered archaeal family B DNA polymerase according to claims 1, 4, 36, 49, 55, 61, 71, 83 or 97, (ii) a DNA template; and (iii) a nucleotide solution.
103. The method of claim 102, wherein the DNA template comprises a clustered array.
104. A kit for performing a nucleotide incorporation reaction, the kit comprising: the altered archaeal B family DNA polymerase according to claim 1, 4, 36, 49, 55, 61, 71, 83 or 97, and a solution comprising second generation fully functional nucleotides.
105. The kit of claim 104, wherein the second generation fully functional nucleotide comprises a detectable label.
106. The kit of claim 104, wherein the second generation fully functional nucleotide has been modified at the 3' sugar hydroxyl group such that the substituent is larger in size than the naturally occurring 3' hydroxyl group.
107. A kit according to claim 106, wherein the second generation fully functional nucleotide comprises a modified nucleotide molecule, the modified nucleotide molecule comprises a purine or pyrimidine base and a deoxyribose portion, and the deoxyribose portion comprises a removable 3'-OH acetal capping group or a 3'-OH thiocarbamate capping group connected to the 3' carbon of the deoxyribose portion.
108. The kit of claim 107, wherein the 3'-OH acetal end-capping group has the structure wherein the *** represents the point of attachment of the 3"-OH acetal capping group to the 3' carbon of the modified nucleotide sugar.
109. The kit of claim 104, wherein the second generation fully functional nucleotides comprise nucleotide molecules comprising a purine or pyrimidine base linked to a detectable label via a cleavable linker.
110. The kit of claim 109, wherein the detectable label comprises a fluorescent label.
111. The kit of claim 109, wherein the cleavable linker is selected from the group consisting of: wherein Z is —O—CH 2 —CH═CH 2 ; n is an integer of 1, 2, 3, 4 or 5; * represents the connection point between the cleavable linker and the purine or pyrimidine base; and ** represents the connection point between the cleavable linker and the detectable label.
112. The kit of claim 104, further comprising one or more DNA template molecules and / or primers.
Citation Information
Patent Citations
Modified polymerases for improved incorporation of nucleotide analogues
US10421996B2
Polymerases, compositions, and methods of use
US11001816B2
Polymerases, compositions, and methods of use
US11104888B2
Sequencing methods using nucleotides with 3′ AOM blocking group
US11293061B2
Nucleic acid sequencing using microsphere arrays
US20050191698A1
